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Deciphering the roles of ΔNp63 in regulating epithelial to mesenchymal
transition, cancer progression and metastasis

Ngoc Hoang Bao Bui, M.S.

Advisory Professor: Elsa R. Flores, Ph.D.

p63 is a member of the p53 family, a well-known tumor suppressor which is
considered the guardian of the genome. The TP63 gene encodes multiple isoforms
that can be categorized into two main isoforms, TAp63 and ΔNp63, which are
expressed in different cellular compartments and have distinct functions in many
biological processes. While the Flores laboratory identified TAp63 as a tumor and
metastasis suppressor, the precise roles of ΔNp63 isoforms in tumorigenesis and
metastasis remain elusive. ΔNp63 is the predominant p63 isoform expressed in the
epidermis and plays essential roles in regulating epidermal development and
homeostasis. Utilizing a ΔNp63-conditional knockout mouse model generated in the
Flores lab, I demonstrated that the loss of ∆Np63 in basal epidermal cells elicits an
“irreversible” epithelial to mesenchymal transition (EMT) via activation of
transcription factors Twist1 and Lef1, leading to a delay in wound healing process in
vivo. I further identified the involvement of a ∆Np63/miR-98, miR-34a/Twist1, Lef1
axis in the regulation of EMT in epidermal cells and wound healing. Moreover, my
work revealed pleiotropic roles of ΔNp63 as either a tumor suppressor or an
oncogene in tumor development and progression. Further, I showed that ΔNp63
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activates its oncogenic program through transcriptional regulation of Lef1 in breast
cancer and lung squamous cell carcinoma. Finally, by generating an in vivo ΔNp63inducible knockdown system, I demonstrated that a dynamic regulation of ΔNp63
enhances metastatic dissemination in breast cancer. Additional work revealed a
TGFβ/microRNAs axis in modulating ΔNp63 expression in breast cancer. The
activation of canonical Smad-dependent TGFβ signaling down-regulates expression
of ΔNp63 via a network of TGFβ-induced microRNAs, including miR-22-3p, miR30a-5p, miR-203a-3p and miR-222-3p. These microRNAs cooperatively function to
regulate expression of ΔNp63 downstream of TGFβ signaling in breast cancer.
Taken together, my work clarified complex context-dependent roles of ΔNp63 in
modulating EMT, cancer progression and metastasis. These findings revealed novel
regulatory networks of ΔNp63 in normal wound repair and cancers, which are
particularly beneficial for the development of diagnostic biomarkers and therapeutic
interventions for chronic wounds and metastatic cancers.
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1. CHAPTER 1: INTRODUCTION

1

Chapter 1: Introduction
1.1 p63, a member of p53 protein family
1.1.1 An overview
The discovery and cloning of TP63 gene, a homolog of the tumor suppressor
TP53, in 1998 has brought enormous attentions to lesser known members of the
p53 family (1). The first p63 knockout (TP63-/-) mouse models were generated and
characterized with striking defects in limb, craniofacial and epithelial development,
which prompted a question on the significance of this p53 family member during
normal development and diseases (2, 3). Since its discovery 20 years ago, there
have been numerous studies focusing on investigating its structure and functions in
many physiological and pathological processes. However, the TP63 locus has a very
complex structure with two separate promoters and multiple alternative splicing,
resulting in transcription of at least six different isoforms. This complexity has
challenged studies that aim to fully understand specific functions of each isoform in
biological processes and diseases, including cancers (4).
Initial reports on p63 expression in human cancers led to contradictory
findings on whether p63 was a tumor suppressor or oncogene due to structural
complexity at the TP63 locus (4). Isoform-specific conditional knockout mouse
models for TAp63 and ΔNp63 have elucidated distinct roles of p63 isoforms in
different cellular compartments, emphasizing the importance of investigating specific
isoforms during the initiation and progression of diseases (5-7).

2

1.1.2 p63 structure and homology to other p53 family members
The TP63 gene locates at chromosome 3q27–29 and encodes an acidic Nterminal transactivation (TA) domain, a DNA-binding domain (DBD) and a carboxyoligomerization domain (OD) (1, 8, 9). The DBD shares the highest homology with
other members of the family (more than 60% identical with p53 and around 85%
identical with p73). Therefore, p63 is able to bind and activate transcription from
canonical p53-responsive elements. Importantly, these structural similarities also
account for complex interactions among p53, p63 and p73, indicating an intricate
relationship among p53 family members in development and diseases. The TA
domain is the least conserved among p53, p63 and p73 with less than 30%
homology (Figure 1) (4, 8).
As mentioned before, the TP63 gene contains two different promoters, which
results in the transcription of multiple proteins categorized into two main isoforms,
TAp63 (with a TA domain) and ΔNp63 (without a TA domain) (9). In addition, both
TAp63 and ΔNp63 transcripts can be transcribed into proteins with at least three
different C-termini termed α, β and γ via alternative splicing. The full-length α
isoforms (TAp63α and ΔNp63α) contain a carboxy-terminal sterile α-motif (SAM)
domain, a protein-protein interaction domain that has been implicated in many
cellular processes. It has been reported that TP53 and TP73 genes can also
transcribe into multiple isoforms through separate promoters and alternative splicing,
adding more layers to the complexity and functional diversity of the family (8-10).
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Figure 1: p53 family members share structural similarities. p63 and p73 share
high structure similarities to p53, especially with more than 60% at the DNA-binding
domain (DBD). p63 and p73 express multiple isoforms which are characterized into
two main categories: TA isoforms and ΔN isoforms. Through alternative splicing,
TP63 and TP73 genes can be transcribed into proteins with at least three different
C-termini termed α, β and γ.
(Figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev
Cancer. 2013; 13(2):136-43, with permission from Copyright Clearance Center)
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1.1.3 TAp63 versus ∆Np63, a tale of two isoforms
Due to significant homology to p53 at the DBD, p63 was predicted to have
transcriptional activities on p53 target genes. Initial in vitro studies showed that
TAp63 isoforms can transactivate p53 targets, whereas ∆Np63 isoforms were
thought to have dominant-negative effects on p53- and TAp63- mediated
transcription due to the lack of the TA domain (1, 11). However, an increasing
number of studies have demonstrated that ∆Np63 has its own transactivation
domain at the C-terminal end and is able to induce transcription of its own target
genes (12-14).
Even though these two isoforms are derived from the same gene locus, they
are expressed in different cellular compartments and have distinct functions in many
biological processes. While TAp63 knockout (TAp63-/-) mice were viable with shorter
lifespan than wild-type mice and developed spontaneous metastatic tumors, ∆Np63
knockout (∆Np63-/-) mice were born with severe defects in epidermal differentiation,
limb and craniofacial development, and died shortly after birth (5, 7, 15). The
predominant isoform expressed in the basal layer of the epidermis is ∆Np63. Several
studies have shown that ∆Np63 maintains the proliferative potential of basal stem
cells, and that loss of ∆Np63 expression in these cells causes disruption in the
proper differentiation of the epidermis (4, 5, 10). ∆Np63 also localizes in basal cells
of the epithelial tissues in mammary glands, trachea, cervix, prostates, tongue and
hair follicles (9). TAp63, on the other hand, is found at very low level in the epidermal
compartment of the skin and acts as a molecular switch during epithelial stratification
program. TAp63 is expressed very early at day E7.5 in mouse embryos, then get

5

Figure 2: TAp63 and ∆Np63 are expressed in different cellular compartments
in the skin. ∆Np63 is the predominant isoform expressed in the basal layer of the
epidermis. TAp63 isoforms are expressed in a specific subset of dermal stem cells
known as skin-derived precursor cells (SKPs), and regulates expression of CDKN1C
to prevent premature senescence.
(Figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev
Cancer. 2013; 13(2):136-43, with permission from Copyright Clearance Center)
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turned off by ∆Np63 to allow maturation of the epidermis during
embryogenesis (16). In stratified epithelium, TAp63 isoforms are expressed in a
specific subset of dermal stem cells known as skin-derived precursor cells (SKPs)
and maintain these cells in quiescence to prevent genomic instability and premature
senescence (Figure 2). TAp63-/- mice developed accelerated aging phenotype,
spontaneous blisters, skin ulceration and delayed wound healing due to premature
depletion of dermal and epidermal precursors (6). Taken together, these findings
suggest distinct contributions of TAp63 and ∆Np63 during development.
p53 is a well-known tumor suppressor for its roles in promoting cell cycle
arrest, cellular senescence and apoptosis through its transcriptional activities on
p21, retinoblastoma (RB) and Bcl-2 family member (17). Due to high structural
similarities between p63 and p53, together with the ability of p63 to activate p53target genes, p63 was initially believed to function as a tumor suppressor.
Interestingly, while TP53 is widely mutated across multiple cancers and TP53
mutation is considered one of the hallmarks of cancers, TP63 is rarely mutated and
frequently found to be overexpressed in multiple epithelial cancers. However, these
studies often failed to distinguish between TAp63 and ∆Np63 isoforms (18, 19).
Early genetic mouse models demonstrated that TP63 heterozygous (TP63+/-) mice
had shorter lifespan than their wild-type littermates and developed various types of
tumors,

including

squamous

cell

carcinomas,

thymic

lymphoma,

lung

adenocarcinomas and hemangiosarcomas. Interestingly, double mutant TP53+/-;
TP63+/- mice exhibited a more aggressive tumor phenotype with higher metastatic
frequency compared to TP53+/- mice, suggesting an important tumor suppressive

7

role of p63 in cancer development and metastasis (20). In another mouse model,
TP63+/- mice showed a significant decrease in spontaneous tumors compared to wild
type mice. Features of accelerated aging and hyperplasia in the epithelium were
often observed in these mice. In this case, TP53+/-; TP63+/- mice had lower tumor
incidence than TP53+/- mice, proposing TP63 as an oncogene in cancers (21). These
contradictory results arose from the existence of multiple p63 isoforms with potential
opposing functions and the lack of isoform specific knockout mouse models.
The first TAp63 knockout (TAp63-/-) mouse model was reported to develop
spontaneous metastatic carcinomas and sarcomas. Strikingly, TAp63 heterozygous
(TAp63+/-) mice displayed a higher metastatic frequency in sarcomas than TAp63-/mice, whereas TAp63-/- and TAp63+/- mice had a similar metastatic frequency in
carcinomas, indicating a tissue-specific contribution of loss of heterogeneity (LOH) in
the aggressiveness of cancers. Moreover, TAp63 was shown to control metastasis
through direct transcriptional activation of Dicer and miR-130b. Overexpressing
Dicer and miR-130b in TAp63-deficient mouse embryonic fibroblasts (MEFs)
decreased migratory and invasive capacity of these cells (15). In another
independent study, TAp63 was also demonstrated as a suppressor of tumorigenesis
in vivo through inducing senescence via oncogenic Ras, and this activity was
independent of p53 (22). Through several in vitro studies, TAp63 has been shown to
not only be induced upon DNA damage but be able to activate transcriptions of
genes involved in apoptosis (23, 24). Recent in vivo data also revealed tumor
suppressive

functions

of

TAp63

in

thymic

lymphoma

through

metabolic

reprogramming via direct transcriptional activation of IAPP (25). Further,
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unpublished data from the Flores lab have unveiled a novel regulatory network of
TAp63 and long non-coding RNAs (lncRNAs) in suppressing tumorigenesis and
metastasis in breast cancer. In summary, these data confirmed TAp63 as a
suppressor of tumorigenesis and metastasis (Figure 3A).
The fact that ∆Np63-/- mice die shortly after birth was a major challenge for
studies that aimed to understand the roles of this isoform in tumorigenesis and
metastasis. Due to its antagonistic effects on transcriptional activities of p53, TAp63
and TAp73, ∆Np63 has been implicated as an oncogene in cancers (1, 4). ∆Np63 is
highly expressed in lung and head and neck squamous cell carcinomas (12, 18, 26).
Moreover, a recent in vivo study utilized a ∆Np63 conditional knockout mouse model
to demonstrate that the ablation of ∆Np63 suppresses thymic lymphomas in p53deficient mice through TAp63-induced transcription of IAPP (25). Napoli et al further
explored oncogenic activities of ΔNp63 through ΔNp63/DCGR8/microRNAs axis and
utilized HDAC inhibitors to induce tumor regression in both thymic lymphomas and
cSCC (27). These accumulating data further emphasize potential oncogenic
activities of ∆Np63 in cancers. However, there are evidences that ∆Np63 is a
suppressor of epithelial to mesenchymal transition (EMT) and potentially cancer
metastasis (28-31). Metastasis suppressive functions of ∆Np63 was also connected
to its inhibitory effects on Erk signaling pathway (29). Interestingly, ΔNp63 was
shown to promote breast cancer cell migration and invasion via transcriptionally
regulating MTSS1 (32). Together, these data indicate that functions of ∆Np63 in
cancer development and metastasis are far more complex (Figure 3B).
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Figure 3: Functions of TAp63 and ∆Np63 in tumorigenesis and metastasis. A,
TAp63 as a tumor suppressor of tumorigenesis and metastasis through various
mechanisms, including metabolic reprogramming via IAPP, regulation of microRNA
biogenesis via Dicer and modulation of novel long non-coding RNAs (lncRNAs). B,
Pleiotropic roles of ∆Np63 as either an oncogene or tumor suppressor in
tumorigenesis and metastasis.
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1.2 ∆Np63 in epithelial development
1.2.1 Epithelial stratification
The skin is the primary barrier to protect the body from dehydration,
environmental insults and pathogens. It is comprised of two compartments, the
dermis and the epidermis that function cooperatively to regulate epithelial
stratification and homeostasis. The epidermis is separated from the dermis by
structure known as the basement membrane. The epidermis is continuously
regenerated by proliferative keratinocytes in the basal layer. The epidermis also
provides a variety of appendages throughout the whole body, including mammary
glands, sweat glands and hair follicles (33-35).
The stratification program starts as early as day E8.5 during embryogenesis
when cells in the ectoderm receive signals to switch to an epidermal fate (33). After
this commitment, basal keratinocytes in the single-layer epidermis begin parallel
divisions to expand the epidermal area. Then, a large portion of these cells start to
divide asymmetrically perpendicular to the basement membrane to generate one
basal and one intermediate suprabasal daughter cell. Later, these intermediate cells
mature into spinous cells which further undergo terminal differentiation into granular
and cornified cells (33, 36) (Figure 4). These epidermal cells not only have different
morphology but express distinct sets of cytokeratin markers. Basal keratinocytes
express keratin 5 (K5) and keratin 14 (K14), whereas suprabasal cells express
keratin 1 (K1) and keratin 10 (K10) (33). Skin stratification is a very complex process
orchestrated by various signaling factors and coordination between multiple cell
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Figure 4: Structure of the epidermis. The skin epidermis comprises of 4 main
layers: basal, spinous, granular and stratum corneum layers. The epidermis is
separate from the dermis by a basement membrane.
(Figure is reproduced from Gonzales KAU, Fuchs E. Skin and Its Regenerative
Powers: An Alliance between Stem Cells and Their Niche. Dev Cell. 2017;43(4):387401, with permission from Copyright Clearance Center)
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populations, especially the tissue-resident stem cells with self-renewal capacity, in
order to maintain structural integrity and homeostasis of the skin (36).

1.2.2 The roles of ∆Np63 in epithelial development
∆Np63-/- mice were born with severe developmental defects in epithelial
stratification and died shortly after birth due to dehydration, which resembled
phenotype of TP63-/- mice (5, 7). While TAp63 is the first isoform to be expressed in
the single-layer epidermis and required for initiation of a stratification program
through activation of K14 expression, ∆Np63 is the most abundant isoform found in
the basal layers of stratified epidermis and essential for both maintenance of
resident stem cell population in the epidermis and terminal differentiation of
epidermal cells (16, 33-35). Moreover, only crossing ∆Np63α-overexpressing
transgenic mice, but not TAp63α, to the TP63-/- mice was able to partially rescue the
epithelialization of the epidermal layer (37, 38).
In one study, ∆Np63-null keratinocytes exhibited unbalanced and accelerated
differentiation, resulting in a failure to form a mature stratified epithelium. There were
keratinocytes expressing K5 in a patchy fashion in the ∆Np63-null skin, indicating
that a subset of ∆Np63-deficient keratinocytes were still able to commit to an
epidermal fate. Interestingly, clusters of keratinocytes were found not only to express
K5 but to retain expression of K8 as well. Co-expression of K5, K1 and K10 was also
found in the epidermal layer of E15.5 ∆Np63-null embryos. These findings suggest
an altered differentiation program associated with premature expression of terminal
differentiation markers in ∆Np63-null keratinocytes. Furthermore, this study
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demonstrated that ∆Np63-null skin showed a significant decrease in cell
proliferation, loss of extracellular matrix and alterations in Notch signaling pathway
(5). Another study utilizing a ∆Np63 conditional knockout mouse model found that
∆Np63-null epidermal cells simultaneously expressed multiple differentiation
markers, including K8, K18, K14 and K10, indicating defects in terminal
differentiation in these cells. However, these ∆Np63-null epidermal cells displayed
hyperproliferation with increased BrdU incorporation and self-renewing capacity with
high expression of induced-pluripotency associated factors such as Oct4, Sox2 and
Nanog. ∆Np63 is believed to regulate multipotency in keratinocytes through
transcriptional activation of DGCR8, a component of the microRNA biogenesis
machinery (7). Taken together, although there are conflicting data on how ∆Np63
regulates proliferation in keratinocytes, it is evident that ∆Np63 is a master regulator
of epithelial development.
One of the important molecular switches that has been shown to control
∆Np63 level between epidermal proliferation and differentiation is microRNA-203
(miR-203). In situ hybridization of miR-203 in the skin showed that miR-203 was
mainly expressed in the suprabasal layer, but not in the basal layer. This expression
pattern was mutually exclusive with ∆Np63 (39). Similarly, human keratinocytes
induced differentiation by calcium treatment in vitro had higher level of miR-203 and
lower level of ∆Np63 than untreated cells. ∆Np63 was shown to be a direct target of
miR-203 during epidermal terminal differentiation (39, 40).
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1.3 ∆Np63 in epithelial to mesenchymal transition (EMT)
1.3.1 The regulatory network of EMT
Since its first description in the early 1980s, the concept of EMT has emerged
as an integral mechanism in many physiological and pathological processes, such
as gastrulation, morphogenesis, wound repair, cell adhesion and movement, fibrosis
and especially cancers (41, 42). Epithelial cells are single layer (or multilayer) cells
that are closely in contact with each other through various structures on cellular
membranes, including adherens junctions, tight junctions, gap junctions and
desmosomes. In addition, epithelial cells show apical-basolateral polarization based
on arrangement of cadherins and integrins on the basement membrane, and
communicate

with

each

other

through

specialized

junctional

complexes.

Mesenchymal or stromal cells, on the other hand, neither organize into cell layers
nor exhibit apical-basal cell polarity. Mesenchymal cells in culture display spindle
shapes with high motility (41, 43-45).
EMT is a process in which epithelial cells undergo changes in their cell
morphology to acquire characteristics of mesenchymal cells, including enhanced cell
motility and invasion. Specifically, EMT typically results in the loss of cell-cell
contacts and is associated with decreased expression of epithelial markers,
including E-cadherin and occludins. Conversely, the expression of mesenchymal
markers, such as N-cadherin and Vimentin are increased during EMT (45, 46). The
reverse process, in which mesenchymal cells transform into a more epithelial state,
is known as the mesenchymal to epithelial transition (MET). These findings suggest
a dynamic nature of EMT to allow cells to transition between the two states of
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Figure 5: The reversible nature of EMT. EMT is a reversible program in which
cells can switch between epithelial and mesenchymal state. Epithelial cells undergo
EMT to become mesenchymal cells. Conversely, mesenchymal cells undergo MET
to reverse to epithelial state. EMT and MET processes are highly regulated by a
complex network of transcription factors.
(Figure is reproduced from Thiery JP, Sleeman JP. Complex networks orchestrate
epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42, with
permission from Copyright Clearance Center)
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epithelial and mesenchymal in a highly plastic fashion (41, 47) (Figure 5). There are
three distinct types of EMT based on different biological contexts that EMT is
involved. Type 1 EMT happens during embryogenesis, gastrulation, organ
morphogenesis and development. Type 2 EMT is related to normal wound repair,
tissue regeneration and organ fibrosis. Type 3 EMT is involved in cancer and
metastasis where tumor cells gain mesenchymal phenotype, allowing them to invade
local stroma and metastasize to distant organs (45).
EMT is mediated by a complex regulatory network of transcription factors,
signaling molecules, and microRNAs. Several transcription factors have been
demonstrated to function as master drivers of EMT, including Twist1/2, Snail1/2 and
Zeb1/2. These transcription factors activate an EMT program by inhibiting epithelial
markers and activating mesenchymal ones through various mechanisms (47-49).
Twist1 binds to E-boxes in the promoter of E-cadherin to repress its transcription
(49). Twist1 interaction with the NuRD complex or polycomb repressor complexes,
PRC1 and PRC2, is also required for the suppression of E-cadherin (50-52).
Likewise, Twist1 induces N-cadherin expression through direct transcriptional
activation (53). Similarly, Snail1 (Snail) and Snail2 (Slug) inhibit E-cadherin
transcription by recruiting polycomb repressor complex 2 (PRC2) to its promoter (5456). In addition, Snail and Slug suppress expression of several other epithelial
markers such as cytokeratins, occludins, claudins and desmoplakin, whereas they
increase expression of pro-invasive genes such as vimentin and fibronectin (49, 57).
Snail also binds to Smad3/4 proteins to promote EMT in the presence of TGFβ (58).
In certain contexts, Snail and Twist factors can cooperate to regulate a same set of
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genes involved in EMT. Interestingly, Zeb1 and Zeb2 are downstream targets of
both Snail and Twist (48, 49, 59). Several signaling pathways, such as Wnt, TGFβ,
Notch, FGF, TNFα and tyrosine kinase receptors, can directly upregulate Twist,
Snail and Zeb factors. These findings suggest an intricate cross-regulatory network
among EMT-inducers to promote cell migratory and invasive abilities (41, 49).
Recently, microRNAs have been intensively demonstrated as integral posttranscriptional regulations of EMT and MET. A complex network of microRNAs
(miRs) has been involved in controlling translation of multiple EMT-associated
factors. Conversely, Twist, Snail and Zeb can also regulate expression of EMTrelated microRNAs, establishing a negative feedback loop to maintain epithelial
homeostasis (60, 61). Among the microRNAs governing EMT, miR-200 and miR-205
families stand out. miR-200 and miR-205 members have been shown to directly bind
to 3’UTR of Zeb1 and Zeb2 to repress their expression (62). In turn, miR-200 family
is inhibited by not only Zeb1/2 but Snail1 to form a double negative feedback loop
(63, 64). Similarly, while Snail1 is a direct target of miR-34 and miR-203, it also
binds to E-boxes in the promoters of miR-34 and miR-203 to regulate their
expression (65, 66). Twist1 has been shown to be repressed by let-7d, miR-29b and
miR-214 (67-69). miR-10b, an onco-microRNA highly expressed in metastatic breast
cancer, is a direct target of Twist1 (70). Furthermore, there are other aspects of EMT
regulated by microRNAs. For example, miR-9 directly targets E-cadherin in
mammary epithelial cells to induce EMT and increase invasiveness (71).
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1.3.2

EMT in wound healing
Wound healing is a physiological response to injury in order to re-establish

normal architecture of the epithelium. The process of wound repair consists of three
partially overlapping but distinct phases: inflammation, formation of new tissue and
tissue remodeling (72, 73). During wound healing, keratinocytes at the migratory
front of the wound undergo morphological and behavioral changes to acquire a more
motile phenotype, and move toward damaged area in a process called reepithelialization. This intermediate state allows the cells to undergo a “partial” EMT
and gain motility to heal the wound while maintaining loose cell-cell contact. At the
end of the re-epithelialization process, these “metastable” cells are able to reverse to
their original epithelial state in order to fully cover the wound with a new epithelial
sheet due to plastic nature of the “partial” EMT (43, 47, 74). Snail2 has been shown
to be involved in triggering the “partial” EMT during wound repair. Upon EGF
treatment in keratinocytes, Erk5 is phosphorylated and induce expression of Snail2,
driving the re-epithelialization process in vitro (75). As such, Snail2-deficient mice
displayed

defects

in

wound

healing

(76).

In

addition,

in

a

N-

Acetylglucosaminyltransferase-V (GnT-V) transgenic mouse model, the upregulation
of Twist and Snail enhanced wound repair process in vivo (77).

1.3.3 EMT in cancer progression and metastasis
Metastasis is a rare occurrence of tumor cells in which they lose contact with
surrounding cells due to the loss of cell-cell adhesions, enter into circulation, and
successfully infiltrate and form metastases at distant organs. EMT has been shown
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to strongly associate with the progression and metastasis of multiple cancers (19,
43, 46). As a key player in metastasis, the EMT program confers malignant traits
associated with invasiveness onto epithelial tumor cells to initiate metastatic
dissemination (78, 79). In addition, the acquisition of stem cell characteristics in
tumor cells after induction of EMT has been observed in multiple cancers, further
confirming the necessity of EMT in cancer stem cell formation and tumor
dissemination (80-85). More importantly, the MET is believed to be essential for
circulating tumor cells to proliferate and seed new tumors at distant organs,
revealing the importance of a “reversible” EMT in the multistep process of metastatic
cascade (86, 87). Two independent studies have shown that while EMT triggers the
dissemination of tumor cells, MET facilitates colonization and establishment of
distant metastases in vivo through two different EMT-associated transcription
factors. Tsai et al. demonstrated in a spontaneous squamous cell carcinomas
mouse model that the spatiotemporal regulation of EMT and MET through Twist1
has a significant role in increasing number of circulating tumor cells in the circulation
and subsequently metastatic frequency (87). Ocana et al., on the other hand,
identified homeobox factor Prrx1 as a novel EMT-inducer. In this study, Prrx1 has
been shown to elicit EMT program in both embryos and tumor cells, whereas the
loss of Prrx1 reverses EMT to MET and increases metastasis. While showing Prrx1
cooperates with Twist1 in inducing EMT and invasion, the study also pointed out that
knocking down Prrx1 alone or both Prrx1 and Twist, but not Twist1 alone, was able
to enhance lung metastasis in a tail vein injection experiment. Strikingly, Prrx1depleted non-tumorigenic cells acquired stem cell properties, suggesting evidence
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for the uncoupling of EMT and acquisition of stemness during cancer metastasis
(86). However, controversies on whether EMT is a prerequisite for metastasis still
exist due to the lack of direct evidence tracing natural occurrence of EMT in
spontaneous cancer metastasis in vivo.
Recently, the contributions of EMT in cancer progression and metastasis
have been greatly challenged by in vivo data showing EMT is not required for
metastasis in several separate mouse models for pancreatic and breast cancers (88,
89). Utilizing a lineage tracing system for EMT in vivo, Fisher et al. provided
evidence for a rare occurrence of EMT events in tumor progression in two
spontaneous metastatic breast cancer models. In this study, a Cre-switchable
fluorescence marker was used to follow the transition of tumor cells from an
epithelial (RFP-positive) to a mesenchymal phenotype (GFP-positive) in vivo. Yet,
the irreversible nature of this system cannot determine whether the GFP-positive
cells eventually returned to epithelial state. This system showed that tumor cells
found in lung metastases were RFP-positive, indicating that neither Vimentin or Fsp1
activated-EMT occurred in these metastatic cells. Further, the authors showed that
the overexpression of miR-200 to inhibit EMT did not impair the formation of
metastases in the lungs (88). In another study, Zheng et al. established genetically
modified pancreatic cancer mouse models to delete two EMT-drivers, Twist1 and
Snail1, and demonstrated that in vivo depletion of neither Twist1 nor Snail1 had
significant impact on initiation, progression and metastasis formation in pancreatic
cancer (89). Interestingly, both of the studies emphasized synergistic effects of EMT
inhibition and chemotherapy in treatment of metastatic cancers (88, 89).
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Figure 6: Intermediate states that cells undergo during the transition from
epithelial to mesenchymal phenotype. During EMT, epithelial cells undergo a
spectrum of phenotype, from epithelial (E) to multiple intermediate (EM) states, then
finally reach mesenchymal (M) state. Different sets of transcription factors are
involved at each step of the transition.
(Figure is reproduced from Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016.
Cell. 2016;166(1):21-45, with permission from Copyright Clearance Center)
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Given the heterogeneous and context-dependent characteristics of cancers,
underlying mechanisms of metastasis may vary across different types and stages of
cancers. The opposing observations on the roles of EMT in metastatic process
reflect the complexity of an open question where further investigations are obligatory
to provide more insights into the issue. Perhaps, instead of a “black and white”
description of EMT in which cells are either in a full epithelial or mesenchymal state,
a spectrum of transitional states between epithelial and mesenchymal characteristics
may provide tumor cells with greater flexibility and plasticity in order to survive,
proliferate and establish metastatic colonies (47, 79). An increasing number of
reports have described the existence of a “partial” EMT in which tumor cells stay in
intermediary phases between epithelial and mesenchymal states and manifest
characteristics from both phenotypes (90-92) (Figure 6). Cells with this hybrid
phenotype exhibit a great dynamic potential to spatiotemporally induce or reverse
EMT, which ultimately favors tumor progression and metastasis (47, 93).

1.3.4 The roles of ∆Np63 in EMT
A knockdown of p63 in human mammary epithelial cells and keratinocytes
disrupted cellular adhesion program and increased anoikis, leading to detachment of
cells from matrix and ultimately cell death. Overexpression of either ∆Np63α or
TAp63γ rescued the phenotype, suggesting an involvement of ∆Np63 in regulation
of cell-cell contact, an important aspect of EMT (94). In another study, the loss of
p63 in non-transformed and transform squamous cells upregulated genes
associated with mesenchymal phenotype such as CDH2 (encodes for N-cadherin),
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WNT5 and ITGA4, and increased migration and invasion. Reasoning that ∆Np63α is
the most abundant isoform expressed in these cells, the authors proposed ∆Np63 as
a potential suppressor of invasion and metastasis (95). In line with these findings,
∆Np63 has been demonstrated to inhibit EMT and cell migration through repressing
Zeb1 expression via direct transcriptional upregulation of miR-205 in metastatic
prostate and cervical cancer (30, 96). Interestingly, while depletion of ΔNp63α and β
isoforms resulted in an EMT phenotype in MCF10A cells, ΔNp63γ exhibited ability to
upregulate TGFβ and induce EMT (97). More importantly, the loss of ΔNp63 in
epithelial-like bladder cancer cells promotes EMT and enhance invasion, while the
induction of ΔNp63 in mesenchymal-like bladder cancer cells triggers MET and
suppresses invasion (31). This mechanism of action resembles the aforementioned
spatiotemporal regulation of Twist1 on EMT during metastasis (87), suggesting a
dynamic regulation of ΔNp63 in cancer metastasis. In a different physiological
context, downregulation of TAp63, but not ΔNp63, in MDCK cell lines induced EMT
with increased expression of Twist1, Snail1 and Slug. TAp63 has been shown to be
essential for tubulogenesis and cell cyst formation (98). However, a mouse model to
address the contribution of ΔNp63 in EMT in vivo is still lacking.

1.4 ΔNp63 in cancer progression and metastasis
1.4.1 Invasion-metastasis cascade
The metastatic cascade includes a series of events that enable epithelial cells
in primary tumors to invade and colonize distant tissues. This process consists of
local invasion into surrounding extracellular matrix, intravasation into the blood
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stream, survival in circulation, arrest and extravasation into distant tissues,
adaptation to new environments to form microscopic lesions, and subsequent
formation of detectable overt metastatic colonies (Figure 7). This multistep process
is orchestrated by a complex network of signaling pathways not only within tumor
cells but between tumor cells and surrounding stromal cells (19, 99).

Figure 7: The multistep process of metastatic cascade. During metastatic
dissemination, migratory tumor cells start to invade surrounding stroma, then
intravasate into the circulation, subsequently arrested at distant sites, extravasate
across the endothelium into new organs and proliferate to establish new metastatic
colonies. (Figure is reproduced from Nieto MA, Huang RY, Jackson RA, Thiery JP.
Emt: 2016. Cell. 2016;166(1):21-45, with permission from Copyright Clearance
Center)

Local invasion
Tumor cells initiate metastatic dissemination process by locally invading
surrounding stroma. During this first step, cancer cells undergo morphological and
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genetic changes, and acquire malignant properties to increase mobility and remodel
extracellular matrix (ECM) in order to move toward the bloodstream (79, 99). There
are three modes which cancer cells are reported to utilize to leave primary tumors:
single cell migration, multicellular streaming and collective migration (100, 101). In
the single cell migration mode, tumor cells tend to lose cell-cell adhesions, become
more motile and leave primary tumors as individual cells. These single epithelial
cells can transform into either mesenchymal (invading cells have spindle shape) or
amoeboid cell types (invading cells have round shape) to invade through local
microenvironment. In the multicellular streaming mode, individual cells move in a
multicellular stream or a small strand of cells toward a chemokine gradient. The
movement of these cells through adjacent stroma is driven by changes in
cytoskeleton structure of individual cells while the cells still maintain a weak transient
contact to each other. Collective migration, on the other hand, involves cohesive
groups or clusters of tumor cells at the invasive front moving together through the
surrounding stroma. These cells retain high expression of E-cadherin to maintain
cell-cell adhesion within the invading clusters (79, 100-102). EMT has been shown
to strongly involve in local invasion of cancer cells, especially in single cell migration
program. Previously, EMT and collective migration-invasion have been proposed to
be mutually exclusive due to opposing phenotype observed in invading tumor cells.
However, recent evidence has raised a question on whether collective invasion is
actually an alternative program to EMT or function cooperatively with EMT to
promote cell invasion (79). In fact, breast cancer metastatic colonies have been
shown to comprise of multiple different clones, indicating that these metastases
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might arise from clusters of tumor cells instead of one single cell during metastatic
dissemination (103). These groups of invading cells are led by “leader” cells at the
invasive front which exhibit mesenchymal traits and secret proteases to degrade
extracellular matrix in order to pave the way for the “follower” cells in the clusters
move through the surrounding stroma (79, 104-106). These findings question the
existence of an intricate interplay between EMT and collective migration-invasion in
the initial step of metastatic cascade. Further researches are necessary to answer
whether EMT and collective migration are mutually exclusive, and whether a
complete block of EMT can prevent collective migration in tumor cells (79).

Intravasation
Intravasation describes a series of events in which invading tumor cells utilize
various mechanisms to enter the bloodstream or lymphatic vessels. The
mechanisms involve transendothelial migration and vessel disruption, which are
facilitated by molecular changes in invasive tumor cells (99). Various signaling
pathways have been shown to contribute to disruption of the endothelium by cancer
cells. Interestingly, transforming growth factor β (TGFβ) has been demonstrated to
function as a molecular switch between single cell and collective migration. Local
and transient TGFβ signaling in the primary tumors enhances single cell migration
and intravasation. However, prolonged TGFβ signaling reduces lung colonization,
suggesting that a spatiotemporal regulation of TGFβ during metastatic cascade is
critical for establishment of overt metastases in distant lungs (107). Interestingly,
increasing evidence has supported the concept of early dissemination of tumor cells
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(108, 109). In a recent study, early disseminated breast cancer cells from the
primary tumors have been demonstrated to account for 80% of metastases in a
Her2-driven breast cancer mouse model (109).

Circulating tumor cells (CTCs)
When invading tumor cells successfully enter the circulation, they have to
survive through a variety of stresses in order to travel to distant tissues and seed
new metastatic colonies. Even though aggressive primary tumors can release plenty
of cells into the circulation a day, only a few of them eventually develop into overt
metastases at distant organs, indicating that metastatic dissemination is a very
inefficient process. Half-life of CTCs in the bloodstream is rather short, ranging from
a few hours to 2 days (110). Given extreme conditions in the circulation, these CTCs
have to undergo dramatic molecular changes to adapt and thrive in the new
environment. They have been shown to develop resistance to anchorage-dependent
growth and anoikis, and escaping mechanisms from innate immune response (99).
In addition, a mixed phenotype of epithelial and mesenchymal traits was often found
in the CTCs, together with increased stem-like properties, further supporting the
importance of the plastic nature of CTCs in the subsequent dissemination to distant
sites (85, 104, 111). These CTCs can travel in the bloodstream as either individual
cells or clusters of cells which are referred as circulating tumor microemboli (CTMs).
These CTMs can derive either from intravasation of invading cell clusters, or less
likely from proliferation or aggregation of individual CTCs. However, while traveling
as clusters might give the CTCs sufficient protection from various attacks in the
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circulation, which type of CTCs is primarily responsible for metastatic colonization
remains unclear (79, 112).

Extravasation
Extravasation starts with the arrest of CTCs or CTMs in blood vessels at
distant organs. Then, tumor cells migrate across the endothelium via a process
called transendothelial migration which is similar to intravasation. After successfully
nesting in the microvasculature of distant tissues, extravasated cancer cells initiate a
proliferation program to form micro-metastases (79, 112). There are ongoing
debates on whether the arrest of CTCs at distant sites is organ-specific based on
evidence that several cancers favor metastatic dissemination to specific organs, for
example breast cancer patients tend to develop metastasis to the bone, lungs and
brain. A hypothesis on establishment of a pre-metastatic niche at distant tissues has
been proposed as a mechanism in which primary tumors release various signals to
create a more hospitable home for disseminated cancer cells in order to facilitate
colonization at specific organs (113).

Metastatic colonization
Metastatic colonization represents the final and most lethal step for tumor
cells during dissemination process. In fact, majority of disseminated cells fail to form
overt metastatic colonies at distant organs. These successfully extravasated cells
may enter a dormancy program in which they retain viability without increase in
tumor cell mass. The dormant tumor cells either are quiescent or maintain an equal
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rate between cell proliferation and apoptosis (112, 114). The dormancy of tumor
cells may explain tumor recurrence in cancer patients after removal of primary
tumors. A number of studies have identified regulators of tumor dormancy in order to
propose potential therapeutic interventions to treat metastatic cancers (115-117).
Recently, a study has utilized an in vivo shRNA screening strategy to identify MSK1
as a regulator of metastatic dormancy in ER+ breast cancer (118).

1.4.2 The roles of ΔNp63 in tumor progression and metastasis
As briefly mentioned in section 1.1.2, given its dominant-negative regulation
on p53, TAp63 and TAp73, and high expression in multiple squamous cell
carcinomas and metastases, ΔNp63 has been argued to function as an oncogene in
human cancers (1, 26, 119). Recent studies have also demonstrated oncogenic
activities of ΔNp63 in primary tumors of thymic lymphomas and cutaneous
squamous cell carcinomas (cSCC) in vitro and in vivo. While Venkatanarayan et al.
identified ΔNp63 as an oncogene in thymic lymphomas in vivo and proposed
targeting ΔNp63/TAp63/IAPP axis as a potential therapeutic approach to treat p53deficient tumors (25), Napoli et al. further explored oncogenic activities of ΔNp63
through ΔNp63/DCGR8/microRNAs axis and utilized HDAC inhibitors to induce
tumor regression in both thymic lymphomas and cSCC (27). These findings indicate
a tumor-promoting effect of ΔNp63 during tumor development. Similar results were
also observed in breast cancer where overexpression of ΔNp63 in patient tumorderived breast cancer sphere cells promotes tumor formation and metastases to the
lungs in xenograft models. The positive regulation of ΔNp63 on metastasis in this
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study was shown through PI3K/CD44v6 axis (120). In another study, ΔNp63 was
shown to promote breast cancer cell migration and invasion via transcriptionally
regulating oncogene MTSS1 (32).

In keratinocytes expressing HPV16 E6/E7

proteins, p63 was able to drive cell migration and invasion via modulating Src-FAK
signaling (121). Adding to the complexity of the pleiotropic roles of ΔNp63 in tumor
progression and metastasis, several studies have demonstrated ΔNp63 as a
suppressor of EMT and potentially metastasis as discussed in section 1.3.4. These
studies also pointed out suppressive activities of ΔNp63 in cancer metastasis
through other mechanisms. Bergholz et al. demonstrated that ΔNp63α inhibits cell
invasion and metastasis in breast cancer by negatively regulating Erk signaling via
direct transcriptional activation of MKP3 (29). More interestingly, Cheung et al.
provided evidence for essential roles of p63 and K14 in initiating a collective invasion
program in breast cancer (122). Utilizing an ex vivo 3D tumor organoid model
derived from luminal B breast cancer mouse model, the authors demonstrated that
“leader” cells at the invading front strongly expressed basal epithelial markers such
as K14 and p63, but not EMT-associated factors, including Twist, Slug and Vimentin,
indicating the initiation of a differentiation program from luminal to basal cells in
these cells. They further showed that K14-positive leader cells are responsible for
collective invasion in multiple breast cancer mouse models, including HER2+ luminal
breast cancer MMTV-Neu model and basal breast cancer C3(1)/Tag model, and in
primary human breast tumors in vivo as well. Importantly, knockdown of either p63
or K14 in tumor cells abrogated the collective invasion program. The depletion of
p63 in organoids resulted in a more dramatic reduction in protrusive tumor cells
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compared to K14-knockdown. These p63-depleted organoids, however, still partially
expressed K14, suggesting that p63 might have other K14-independent functions in
modulating collective invasion. This is not surprising given the fact that K14 has
been shown to be a direct downstream target of ΔNp63 in basal epidermal cells
(123, 124). These findings further suggest an intricate involvement of ΔNp63 in
cancer metastasis. Perhaps, ΔNp63 may function as a molecular switch between the
two invasion programs given its crucial roles in controlling cell fate and
differentiation. This is particularly important in the context of both EMT-induced
single cell invasion and collective invasion have been demonstrated to contribute to
metastatic dissemination of breast cancer, and whether the two programs are
mutually exclusive still remains unclear (79, 107).
In addition, several multiplatform pan-cancer studies have revealed the
amplification of TP63 gene locus, overexpression of ΔNp63 and the activation of
TP63/ΔNp63-driven

transcriptional

network

across

multiple

squamous-like

carcinomas (125, 126). Hoadley et al. developed an integrated subtype classification
for 12 different cancers based on a cluster of cluster assignment method. This crossplatform classification not only defined 13 distinct integrated molecular subtypes, but
identified genomic- and pathway-based determinants of these subtypes as well.
Intriguingly, this study demonstrated that lung squamous cell carcinoma (LUSC),
head and neck squamous cell carcinoma (HNSC), some bladder cell carcinoma
(BLCA) and a few lung adenocarcinoma (LUAD) share similar molecular signatures
and are classified into C2-squamous like subtype. Amplification of TP63, SOX2 and
PIK3CA, together with loss of CDKN2A, RB and TP53 are often observed in these
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tumors. Due to previous reports on transcriptional similarities between breast cancer
(BRCA) and LUSC, the authors then identified common molecular networks between
two subtypes. More interesting, C2-squamous like tumors showed higher TP63
(ΔNp63α and TAp63γ) expression and transcriptional activation compared to C4BRCA/basal tumors. These features distinguish C2-subtype from others. Potential
compensatory functions of p63/p73-regulated pathways for impaired p53 have also
been proposed in HNSC and BRCA, further indicating the significance of
p53/p63/p73 family transcriptional activities in these cancers (126). Recently,
Campbell et al. further explored distinguishing molecular features in squamous cell
carcinomas (SCCs), including genomic, epigenetic, gene and microRNA expression,
and pathway signatures. Consistent with Hoadley’s study, copy number gain at
chromosome 3q and overexpression of ΔNp63 in SCCs were also reported in this
study. Additionally, the authors unveiled distinctive pathways for SCCs that are
involved in DNA damage, EMT and immune response. Particularly, TP53/63/73associated pathways were significantly enriched in SCCs. There was a strong
expression correlation between microRNA linked to EMT, particularly miR-944, and
ΔNp63 mRNAs across the pan-SCC dataset, which was later shown to be related to
differential methylation at transcriptional start sites and other CpG islands of ΔNp63
(125). Taken together, these integrated pan-cancer analyses reveal the importance
of p63 signaling pathways in defining molecular subtypes of different cancers.
Notably, the use of these genomic, epigenetic and expression signatures provides
additional molecular footprints for different types/subtypes of cancer that can be
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beneficial for

therapeutic intervention, especially p63-isoform specific targeted

therapies.
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Chapter 2: Materials and methods
Content of this chapter is partly based on the following articles:


Hussein Abbas*, Ngoc Bui*, Kimal Rajapakshe, Justin Wong, Preethi Gunaratne,
Kenneth Y. Tsai, Cristian Coarfa and Elsa R. Flores. Distinct TP63 isoforms
transcriptional signatures predict tumor progression and clinical outcomes.
Cancer Research (2018) 78(2), 451–62. *co-first authors
Copyright permission is not required since Cancer Research journal policy states
“Authors of articles published in AACR journals are permitted to use their article
or parts of their article in the following ways without requesting permission from
the AACR.”



Bui NH*, Flores González RE*, Chakravarti D, Coarfa C, Tsai KY and Flores ER.
ΔNp63 regulates epithelial-mesenchymal transition during wound healing. In
preparation

2.1 Primary mouse keratinocyte isolation and culture
Keratinocytes (KCs) were isolated from skin of E18.5 embryos of wild-type
(WT), ΔNp63-/-, and TAp63-/- mice using Dispase II (Roche) as previously described
(6). The separated epidermis was then minced and incubated in 0.25%
Trypsin/EDTA (Corning) for 20 minutes. Cells were then plated on collagen-coated
flasks (50 μg/ml) (BD Bioscience) in defined K-SFM medium (GIBCO). WT and
TAp63-/- keratinocytes were cultured in Ham’s F12:DMEM (3:1), and ΔNp63-/keratinocytes were cultured in mouse ES media as previously described (7).
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2.2 Cell lines and culture conditions
Normal human epidermal keratinocytes (NHEK) were purchased from Lonza
and cultured in KGM-Gold media (Lonza). Human mammary epithelial MCF10A,
human breast cancer MCF10DCIS.com and MCF10CA1D.cl1 cell lines were
obtained from Barbara Ann Karmanos Cancer Institute (Detroit, MI), and cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (1:1) media containing 5% horse
serum, 1.05 mM CaCl2, 10 μg/ml insulin, 20 ng/nl epidermal growth factor, 500 ng/ml
hydrocortisone, 10 mM HEPES and 100 μg/ml primocin. Human lung squamous cell
carcinoma HCC95 cell line was kindly provided by Dr. John Heymachs at UT MD
Anderson Cancer Center (Houston, TX), and cultured in RPMI 1640 media
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Human
kidney clear cell carcinoma Caki-1 cell line was purchased from ATCC, and cultured
in McCoy’s 5A modified media supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin.

2.3 In vitro scratch assay.
Keratinocytes were plated on 6 well plates on top of J2-3T3 feeder cells.
Before performing the assay, the feeders were removed using 0.02% EDTA. Then, a
scratch was made using a 200µl pipette tip. The wound closure was monitored over
a 24-hour period using time-lapse microscopy. Time-lapse images were taken every
10 min. For the analysis, individual cells were followed using the time-lapse images
and their path lengths were quantified and compared.
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2.4 In vitro Boyden Chamber assay.
Human and murine keratinocytes were resuspended in 500 μl of media with
2% FBS (3 × 104 cells/insert) and added to top chambers of the cell migration and
invasion culture inserts (354578, 354480; BD Biosciences). 750 μl of media with
20% FBS was added to the bottom chamber. The chamber plates were incubated
for 24 hours at 37oC. The cell were then fixed and stained with Diff-Quik kit
(Siemens). Cells from the top chamber were removed using cotton swap. The
remaining cells were counted with a Zeiss AxioObserver A1 inverted microscope.

2.5 In vivo wound healing assay.
ΔNp63-conditional knockout mice (ΔNp63fl/fl) were crossed to RosaM/M mice,
and K14CreER+ mice to generate the ΔNp63fl/fl, RosaM/M, K14CreER+ mice used for the
in vivo wound healing studies. Mice were anesthetized using inhaled isoflurane and
a 1 cm wound constrained to the epidermis was made using 250 µl of DXB
compound (Clearista). Tamoxifen (100 mg/mL) was then applied topically for three
constitutive days to induce recombination. Control mice were treated with 100%
ethanol. Mice were euthanized at days 1, 4, and 8 after wounding, and the skin
section around the wounds were collected. One half of the epithelium was fixed in
10% formalin, embedded in paraffin and sectioned onto slides. Sections were then
stained for hematoxylin and eosin (H&E), and the wound sizes were measured and
analyzed. The other half of the tissue was frozen in OCT medium (Tissue Tek) using
liquid nitrogen, and sectioned onto slides. Frozen sections were used to assess
recombination status using fluorescence microscope.
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2.6 Immunohistochemistry
Paraffin embedded tissue sections were prepared as described previously
(20). Sections were incubated with anti-ΔNp63 (619002, Biolegend, 1:1000), Twist1
(sc-81417, Santa Cruz, 1:100), Lef1 (2230S, Cell Signaling, 1:200), or Ki67
(ab15580, Abcam, 1:1000) antibody overnight at 4oC in a humid chamber followed
by incubation with horseradish peroxidase conjugated-secondary antibody in the
ImmPRESS kit (Vector lab) for 45 minutes at room temperature, then followed by the
DAB kit (Vector lab). Quantification for ΔNp63-positive cells and signal intensity were
done using Tissue Studio 4.3 software. Staining score was calculated using the
following formula: Score = % positive cells x Average signal intensity.

2.7 Immunofluorescence
Paraffin embedded tissue sections were prepared as described previously
(20). Sections were incubated with anti-GFP (ab13970, Abcam, 1:500), Ki67
(ab15580, Abcam, 1:100), Cytokeratin 5 (ab53121, Abcam, 1:500), E-Cadherin
(ab76319, Abcam, 1:200), Vimentin (ab92547, Abcam, 1:200) and Cytokeratin 14
(LS-C22637, LifeSpan Biosciences, 1:500). For secondary antibodies, Alexa Fluor
568 goat anti-rabbit (703-545-155, Life Technologies, 1:500), FITC goat anti-guinea
pig (Jackson ImmunoResearch, 1:500), or Alexa Fluor 488 donkey anti-chicken
(Jackson ImmunoResearch, 1:500) antibodies were used.
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2.8 qRT-PCR
Total RNA was isolated from cell pellets using miRNeasy kit (Qiagen).
Complementary DNA was synthesized from total RNA using SuperScript FirstStrand Synthesis System (Invitrogen). qRT-PCR reactions were performed with the
7500 Fast real-time PCR System using Power SYBR Green PCR Master Mix (Kapa
Biosystems) in accordance with the manufacturers’ protocols. The following primers
were used: human Twist1: 5’-GGAGTCCGCAGTCTTACGAG-3’ (forward) and 5’TCTGGAGGACCTGGTAGAGG-3’

(reverse),

CGGGTACATAATGATGCCAA-3’

(forward)

TCACTGTAAGTGATGAGGGGG-3’

(reverse),

GCCGGAGACCTAGATGTCATTG-3’
CACGCCCTGATTCTTGTGAA-3’

human
and
murine

(forward)
(reverse),

Lef1:

5’-

Twist1:
and

murine

5’-

Lef1:

5’5’5’-

CCCACACGGACAGTGACCTA-3’ (forward) and 5’-TGGGCTCCTGCTCCTTTCT-3’
(reverse). Human GAPDH: 5’-TCTCTGCTCCTCCTGTTC-3’ (forward) and 5’GCCCAATACGACCAAATCC-3’

(reverse),

and

murine

GAPDH:

5-

‘TCACCACCATGGAGAAGGC-3’ (forward) and 5’-GCTAAGCAGTTGGTGGTGCA3’ (reverse) were used as internal controls. Each sample was run in triplicate.
Ct values for each gene were calculated and normalized to Ct values for GAPDH.

2.9 miRNA TaqMan assays
Total RNA were isolated from cell pellets using miRNeasy kit (Qiagen). 500
ng of total RNA was used to synthesize complementary DNA with the Two-Step
TaqMan MicroRNA Assay kit (Applied Biosystems) in accordance with the protocol.
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qRT-PCR was performed with the 7500 Fast real-time PCR System, TaqMan PCR
master mix (Applied Biosystems), and TaqMan probes (Applied Biosystems) for hsamiR-34a-5p (ID: 000426), hsa-miR-98-3p (ID: 472125_mat) and mmu-miR-98* (ID:
462189_mat), hsa-miR-22-3p (ID:000398), hsa-miR-30a-5p (ID:000417), hsa-miR203a-3p (ID: 000507) and hsa-miR-222-3p (ID:002276) . Each sample was run in
triplicate. Ct values for miRNAs were calculated and normalized to Ct values
for either human RNU6B (ID: 001093, Applied Biosystems) or murine snoRNA234
(ID: 001234, Applied Biosystems)

2.10 ChIP assay
ChIP was performed with nuclear extracts from cell pellets as previously
described (6, 24). Briefly, cells were grown to 90% confluence. Cells were fixed with
1% formaldehyde and neutralized by glycine. Samples were sonicated on ice to
obtain 500-1000bp DNA fragments. 2µg of ΔNp63-specific antibody (sc-8609, Santa
Cruz), Smad2/3-specific antibody (sc-133098 X, Santa Cruz), Smad2/3 antibody (sc133098 X, Santa Cruz) or control IgG (sc-2027, Santa Cruz) was added to each
sample and incubated overnight at 4oC. Then, protein-DNA complex was
precipitated using protein A agarose beads/Salmon sperm DNA (Millipore). qRTPCR was performed with the following primer sequences specific for p63- or
Smad2/3-binding sites: human Twist1: 5’-CGCTCTTCTCCTCTGCCC-3’ (forward)
and

5’-

TCTTCCTCGCTGTTGCTCAG-3’

(reverse),

human

Lef1:

5’-

GCGTTGGTGACGGACTTTTT-3’ (forward) and 5’- TGGAACCCTAATCCCCGAGA3’ (reverse), human miR-203a-3p: CAGATCTGGTGGCTGTGTTCT (forward) and
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ATACCCTAGAGCCCCCTTCAG

(reverse),

miR-30a-5p:

TTGGTTAGGGTTGCTCTTCCC

(forward)

(reverse),

GAAGATTGGCCTCTGCGGTA

human

miR-22-3p:

GCCGGCTGTCTGGTTTCTAT

and

human

(reverse),

AGTCACTGTCAGCAGTTCCC

human

(forward)

and

miR-222-3p:

GGCTCTTTTCTCACTTGCGG (forward) and GGTCTACAACATGACAGTCTGGA
(reverse). Primer sequences for non-specific binding sites were as follows: human
Twist1

promoter:

5’-AATTCTAGAGGCACCCAGGAG-3’

GCCCTCTGAATACCAAACTGGA-3’,

human

(forward)

Lef1

and

promoter:

5’5’-

GCAGAGGCAACAAGGACTGA-3’ (forward) and 5’-TGGCTTCCTCTTGCTCACTG3’ (reverse), human miR-203a-3p: CTTGTCTGAGGCTAGGGCTGT (forward) and
CAGCAACCCAATGACACCCG
CGGCCCATGTGGAAATGTCT

(reverse),
(forward)

and

human

miR-30a-5p:

TAGAGCCCCCTTCAGCACTT

(reverse), human miR-22-3p: CCGTATGTTGTAGATGAGGGG (forward) and
CAGATCTGGTGGCTGTGTTCT

(reverse),

human

miR-222-3p:

TTCTTAACGGTGTGGGAGGC (forward) and AGAAGTGAACAAAAACTGCCAC
(reverse).

2.11 Western blot analysis
50µg of total protein were electrophoresed on 10% SDS-PAGE gel and
transferred to PVDF membrane as previously described (6, 127). Blots were then
probed with anti-ΔNp63 (619002, Biolegend, 1:500), E-cadherin (3195, Cell
Signaling, 1:1000), Vimentin (ab92547, Abcam, 1:1000), Twist1 (sc-81417, Santa
Cruz, 1:250), Lef1 (2230S, Cell Signaling, 1:1000), Snail (3879S, Cell Signaling,
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1:1000), Zeb (sc-10572, Santa Cruz, 1:500), Smad2 (sc-101153, Santa Cruz,
1:500), Smad3 (9523S, Cell Signaling, 1:1000), phospho-Smad2 (ab53100, Abcam,
1:500),

and phospho-Smad3 (9520S, Cell Signaling, 1:500) overnight at 4oC.

Horseradish peroxidase conjugated- secondary antibodies against either murine or
rabbit IgG (Jackson lab) were incubated with the blots for 1 hour at room
temperature. Actin (A5060, Sigma) or Hsp90 (ab13495, Abcam) was used as
loading control. Detection was performed using ECL Plus Kit (Amersham) or Licor
system.

2.12 Lentiviral shRNA infection
Lentivirus-based vectors (3 μg) overexpressing mmu-miR-34a (SBI), mmumiR-98-3p (SBI) or empty vector (as control) were transfected into 293T cells along
with 3 μg of lentivirus packaging vectors, pCMV-VSVG and pRSV-REV, using XtremeGENE HP (Roche) in accordance with the manufacturer’s protocol. After 48
hours post-transfection, supernatants were collected, filtered and added to ΔNp63-/keratinocytes for 48 hours in the presence of 8 μg/ml Polybrene (Santa Cruz).
2 μg/ml of purmocyin was added to the media 48 hours after infection for 2 days.
Cells were then changed to fresh media for further analysis. Infected cells were
analyzed by miRNA TaqMan assay to determine the level of miRNA overepxression.
These cells were further analyzed for migration and invasion capacity using Boyden
chamber assay as described above.
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2.13 siRNA transfection
5x105 cells per 60 mm dish were transfected with 40 nM siTwist1-mouse
(SASI_Mm01_00043025, Sigma) or siLef1-mouse (SASI_Mm01_00158789, Sigma)
or siLef1-human (SASI_Hs02_00349169 and SASI_Hs01_00151600, Sigma) or
si∆Np63

(Sense:

CAGCAGCAUUGAUCAAUCUUA,

Antisense:

UAAGAUUGAUCAAUGCUGCUG) using Lipofectamine RNAi Max (Invitrogen)
according to manufacturer’s protocol. The cells were collected 48 hours posttransfection for further analysis. Transfected cells were analyzed by western blot to
determine knockdown efficiency. These cells were further analyzed for migration and
invasion capacity using a Boyden chamber assay as described above, or for cell
proliferation and anchorage-independent colony formation.

2.14 MicroRNA mimics and inhibitors transfection
5x105 cells per 60 mm dish were transfected with 40 nM microRNA inhibitors
(ThermoFisher) or 6 nM microRNA mimics (ThermoFisher) using Lipofectamine
RNAi Max (Invitrogen) according to manufacturer’s protocol. The cells were
collected 48 hours post-transfection for further analysis. The microRNA inhibitors
used to target microRNAs are as followed: miR-203a-3p (MH10152), miR-30a-5p
(MH11062), miR-22-3p (MH10203), miR-222-3p (MH11376) and negative control
(4464077) (ThermoFisher). The microRNA mimics purchased from ThermoFisher
are miR-10b-5p (MC11108), miR-21-5p (MC10206), miR-22-3p (MC10203), miR30a-5p (MC11062), miR-141-3p (MC10860), miR-181a-5p (MC10421), miR-200a-3p
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(MC10991), miR-203a-3p (MC10152), miR-222-3p (MC11376) and negative control
mimics (4464058).

2.15 Plasmid transfection
0.5×106 cells were plated in 6-cm dishes. 1µg of plasmids was transfected
into the cells using X-tremeGENE HP DNA transfection reagent (Sigma) according
to manufacturer’s protocol. The cells were collected 48 hours post-transfection for
further analysis. Transfected cells were analyzed by western blot to determine
overexpression efficiency. These cells were further analyzed for cell proliferation and
anchorage-independent colony formation.

pcDNA3.1-DYK-Lef1 and pcDNA3.1-

DYK-empty plasmids were obtained from Genscript. ΔNp63α ORF was cloned into
pcDNA3.1-Myc-empty plasmid.

2.16 Cell proliferation assay
0.5x104 cells were plated in 6 replicates in 96 well-plate subsequent to
siRNA/DNA transfection overnight. Cell were then incubated with 10 nM EdU (5’ethynyl-2’-deoxyuridine) for either 1.5 hours (MCF10CA1D) or 4 hours (HCC95) or
48 hours (Caki-1), and stained using the Click-iT EdU microplate assay (Invitrogen)
according to manufacturer’s protocol. Images were captured using an Olympus IX83
inverted fluorescent microscope. Quantification of the percent of cell proliferation
was obtained using Celigo and Incucyte instruments.
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2.17 Growth curve
0.2x104 cells per well were plated onto 96-well plates. The plates were read
with the IncuCyte (Essence Bioscience) every 6 hours for 72 hours. Cell confluency
or density was measured using IncyCyte Zoom software.

2.18 Soft agar assay
5x104 cells were seeded in 1 ml of 0.3% top agar layer in six-well plates
subsequent to siRNA/DNA transfection. The base layer was composed of 1.5 ml of
0.6% agar in culture media. Plates were allowed to solidify at room temperature,
then 1.5 ml of culture media was added to each well. Plates were incubated at 37
°C, and the media was changed every 3 days for 14 days. Colonies were then
stained with 0.005% crystal violet for 1 hour. The number of colonies per 10X field
was counted using Olympus IX83 and Zeiss Observer.Z1 inverted fluorescent
microscopes.

2.19 Luciferase reporter assay
3’UTR of TP63 gene was cloned into pLightSwitch backbone (pLightSwitch3’UTR-TP63) (Activemotif). One day before transfection, 1x104 cells per well were
plated onto white 96-well plates. Next day, 100 ng empty vector or pLightSwitch3’UTR-TP63 vector was transfected together with 20 nM microRNA mimics into the
cells using Lipofectamine 2000. 48 hours post-transfection, the plates were kept at
-80oC overnight. On the day of the assay, the plates were thawed at RT for at least
45 minutes prior to assaying luciferase activity. Then, 100 µl of LightSwitch assay
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solution (Activemotif) was added to each well, incubate for 30 minutes at RT in the
dark. Each well was read for 2 seconds in a plate luminometer (Promega).

2.20 Site-directed mutagenesis
Mutated versions of the 3’UTR of TP63 was generated using Q5 Site-directed
mutagenesis kit (New England Biolabs) following manufacturer’s protocol. Primers
with substitution mutations of the seed sequences of the microRNAs were designed
using primer design software NEBaseChanger (New England Biolabs). The following
primers were used to generate mutant versions of the 3’UTR of TP63 for each
microRNA tested: miR-22-3p: CAACAAGCATcgtcgaTTGCAAACCCATTAAGGGG
(Forward)

and

CAGAAGTTTACAGTGCTTATTAC

atgCTTTCTCTCTCTAAGGTTTACAATAG
ttgtAGCCTCTACATGCAGAGT

(Reverse),
(Forward)

(Reverse),

and
miR-203a-3p:

aagTTCTAGTGATGATGGTTC

(Forward)

tacaCAGTAATATAAAATATACCAACAC

(Reverse),

CTTGCAGAACacatcgTGCCATGGCTAGGTAG

miR-30a-5p:

(Forward)

and
miR-222-3p:
and

CTATAGTTTTGAAGGCTTAAAG (Reverse).

2.21 In vivo mammary fat pad injection
2x106 cells mixed 1:1 ratio with growth factor reduced matrigel (BD
Biosciences) were injected into the left and right mammary fat pads of nude mice.
After two weeks post-injection when the tumors became palpable, the mice were fed
with either control diet or doxycycline (dox) diet (200 mg/ kg, Bio-Serv) to induce
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expression of the sh∆Np63. At the end of the experiments, all the mice were
euthanized and performed necropsy to collect tumors and internal organs for further
analysis. Tumor sizes (length and width) were measured using a caliper. Tumor
volume

was

calculated

using

the

following

formula:

Tumor

volume =

1/2(length × width2)

2.22 In vivo tail vein injection
Cells were trypsinized and washed with HBSS (without Mg2+ and Ca2+),
filtered through 70 µM cell strainers and resuspended in HBSS (without Mg2+ and
Ca2+). 5x105 cells were injected into nude mice via tail vein. The mice were fed with
either control diet or dox diet (200 mg/ kg, Bio-Serv) one day before injection, and
continued with the diet for 8 weeks. Then, the mice were euthanized and the lungs
were collected for further analysis.

2.23 Isolation of RPF-positive cells in the lungs
The cells were infected with Firefly luciferase-T2A-RFP-Puro (Biosettia) to
make stable cell line expressing RFP, then injected to nude mice via tail vein. The
mice were fed with either control diet or dox diet one day before injection. 48 hours
post-injection, the mice were euthanized, and the lungs were collected and
dissociated as previously described (128, 129). In brief, the lungs were perfused with
cold PBS until they were clear of blood. 2 mL of dispase (50 U/mL, BD Bioscience)
was injected into the trachea just until the lungs inflated. Then, 0.5 mL of 1 % lowmelting agarose was injected to the lungs, cover chest cavity with crushed ice for 2
minutes to set agarose. The lungs were dissected out and placed in cold PBS on
48

ice. After that, the lungs were minced into small pieces in PBS, and
collagenase/dispase (100 mg/mL, Roche) was added to the tissue homogenates.
After 45 minutes rotating at 37oC, digested tissue was treated with 1 % DNase
(Sigma) and lysed of red blood cells (RBC) using RBC lysis buffer (BioLegends).
Cell pellets were then used for cell sorting to analyze population of RFP-positive
cells.

2.24 miRNA-mRNA functional pair analysis
The functional pair analysis was performed for downregulated miRNAs and
upregulated mRNAs in the miRNA-Seq and RNA-Seq data from wild type and
ΔNp63-/- keratinocytes (7). Predicted targets of miRNAs enriched in the upregulated
genes were determined using the TargetScan and the exact Fisher’s test (q < 0.05).

2.25 Bioinformatics analysis
The primary and processed data for 9578 tumor and 730 normal samples
were downloaded from The Cancer Genome Atlas website between July 2014 and
February 2015. We aligned all TCGA sequencing data to Genome Reference
Consortium Human Reference 38 (hg38) in order to identify all genes and TP63
isoforms (α, β, γ for TAp63 and ΔNp63). TAp63 signatures were derived from
epidermal cells P1 TAp63-/- and wild type mice at embryonic day 18.5 (6). For ΔNp63
murine gene signature, we used previously published transcriptome profiles (7). For
putative tumor suppressor role of the TAp63 or ΔNp63, we identified genes that
were significantly changing and in the same direction in both TAp63-/- (or ΔNp63-/-)
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and the corresponding tumor signature. For oncogenic roles, an inverse approach
was taken. PCSS was identified separately for each gene signature and for each
role (eg. tumor suppressor or oncogene) using association of gene scores and
survival that conforms with the predicted function. The highest-ranking genes were
then combined to establish a robust PCSS. Z-scores were used for all activity
scoring then ranked by the highest and lowest 25th percentile quartiles. We utilized
BP, KEGG and Reactome compendiums for pathway analysis.

2.26 NanoString

microRNA

analysis

to

identify

differential

expressed

microRNAs
2x105 MCF10DCIS cells were treated with TGFβ1 (10 ng/mL) for 72 hours,
then collected for total RNA using miRNaesy Kit (Qiagen) following manufacturer’s
protocol. Experiments were done in quadruplicate. Then, RNA samples were run in
the NanoString human microRNA panel (NanoString) following manufacturer’s
protocol. Briefly, annealing master mix was prepared and added to each tube of a 12
x 0.2 mL strip tube. RNA was then added to each tube. Samples were annealed,
ligated and purified in a thermocycler following the kit’s protocol. Next, samples were
hybridized with Capture probeset for 12 hours followed by post-hybridization
processing with the nCounter Analysis System.
Raw array data files (RCC) and miRNA panel file (RLF) were read using
nSolver 3.0 software (NanoString). Data Quality metrics was also generated by this
software with the default parameters (Field of view (FOV) <75, Binding density is
between 0.05 and 2.25, Positive control linearity R2 > 0.95, 0.5fM positive control
limit of detection < 2 STDEV).

Comparison of normalization methods for
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NanostringDiff (130), Housekeeping genes and NanoStringNorm (131) were made.
Raw NanoString counts were normalized using NanostringDiff package. Normalized
data were log2 transformed. Limma package (132) was used for gene differential
analysis between two groups. Significant genes were selected as adjusted p value
<0.05 and fold change greater than 2. Heatmaps of the significant genes were
generated by gplots package of bioconductor.
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Chapter 3: ∆Np63 regulates epithelial to mesenchymal transition during wound
healing via transcription factors Twist1 and Lef1
Content of this chapter is partly based on the following manuscript:


Bui NH*, Flores González RE*, Chakravarti D, Coarfa C, Tsai KY and Flores ER.
ΔNp63 regulates epithelial-mesenchymal transition during wound healing. In
preparation

3.1 Introduction and rationale
Given the crucial roles of ΔNp63 in maintaining epithelial structure and
homeostasis and its high expression in basal keratinocytes, a major component
participating in wound repair, ΔNp63 may play an important role during wound
healing process. Therefore, I aimed to investigate whether the loss of ΔNp63 in
basal epidermal cells could have any significant impact on normal wound repair by
utilizing a conditional ΔNp63-knockout mouse model and an in vivo cutaneous
wound healing model.

3.2 Results
3.2.1 The loss of ∆Np63 induces EMT in mouse and human keratinocytes in
vitro
Keratinocytes isolated from ∆Np63-/- mice are reported to be highly
proliferative and express several pluripotency-associated factors including Oct4,
Sox2 and Nanog (7). Strikingly, these ∆Np63-deficient epidermal cells exhibited

53

Figure 8: Depletion of ΔNp63 promotes an epithelial to mesenchymal
transition in mouse and human keratinocytes in vitro. A-D, cell morphology of
Wild-type (WT) (A) and ΔNp63-/- mouse keratinocytes (KCs) (B), and WT (C) and
ΔNp63 knocked-down normal human epidermal keratinocytes (NHEK) (D). E-F,
western blot analysis for expression of EMT-related factors in WT and ΔNp63-/- KCs
derived from three independent embryos (E) and WT and ΔNp63 knocked-down
NHEK (NHEK-shΔNp63) (F) using the indicated antibodies. Actin and Hsp90 were
used as loading controls.
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dramatic change in morphology from epithelial-like to elongated spindle-like shape
(Figure 8A-B), suggesting a transition from epithelial to mesenchymal state. The
same

morphological

change

was

observed

in

normal

human

epidermal

keratinocytes (NHEKs) when ΔNp63 was knocked using shRNA (Figure 8C-D). To
ask if these morphological changes were related to EMT, several hallmarks of EMT
were examined. Both mouse and human ΔNp63-depleted keratinocytes showed
decreased expression in E-cadherin, an epithelial cell adherens junction protein,
while level of vimentin, a marker for mesenchymal cells, was upregulated. In
addition, several EMT-associated transcription factors, including Twist1, Snail1, Lef1
and Zeb1, were also elevated in both ∆Np63-/- KCs and NHEK-shΔNp63 cells
(Figure 8E-F). EMT is often accompanied with increase in cell motility (47).
Therefore, I next asked if the ablation of ΔNp63 led to increased cell migration and
invasion in both KCs and NHEKs in vitro. Indeed, ∆Np63-/- KCs showed significant
increase in cell movement toward scratch sites compared to WT and TAp63-/- KCs.
Especially, ∆Np63-/- KCs demonstrated a movement pattern of individual cells with
loose cell-cell contact while TAp63-/- KCs moved toward wounded sites as a whole
sheet of cells (Figure 9A-B), further confirming the induction of EMT upon ∆Np63
depletion. Moreover, ∆Np63-/- KCs also exhibited higher migratory and invasive
capabilities compared to WT KCs (Figure 9C-D). Similar increase was observed
when ∆Np63 was knocked down in NHEKs (Figure 9E-F). Taken together, these
data indicate an induction of EMT upon depletion of ΔNp63 in epidermal cells.
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Figure 9: Depletion of ΔNp63 increases cell migration and invasion in mouse
and human keratinocytes in vitro. A-B, in vitro scratch assay using WT, ΔNp63-/-,
and TAp63-/- KCs. Representative images for time points for 0, 8 and 24 hours (A)
and measurement of distance traveled by WT, ΔNp63-/-, and TAp63-/- KCs (B),
Asterisks indicate statistical significance, p ≤0.0003 versus WT KCs. C-D, Boyden
chamber assay for migration (C) and invasion (D) capacity of WT, ΔNp63-/-, and
TAp63-/- KCs. E-F, Boyden chamber assay for migration (E) and invasion (F)
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capacity of WT NHEK and NHEK-shΔNp63, Asterisks indicate statistical
significance, p < 0.0001 versus WT NHEK.
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3.2.2 ΔNp63 depletion delays wound healing process in vivo
Wound healing is a normal physiological process to re-epithelialize injured
skin areas. Basal keratinocytes play crucial roles during the re-epithelialization (73).
Given the important roles of ΔNp63 in biological functions of keratinocytes, we asked
if ΔNp63 contributes to regulation of wound repair. To further characterize the
contribution of ΔNp63 in wound healing process, an in vivo cutaneous wound
healing model was developed to utilize a ΔNp63-conditional knockout mouse model
(ΔNp63fl/fl) generated in the Flores lab (7). These mice were crossed to RosaM/M
mice and K14CreER+ mice to generate ΔNp63fl/fl, RosaM/M, K14CreER+ mice. The triple
mutant mice expressed a tdTomato lox-stop-lox (LSL) GFP reporter cassette
inserted into ROSA26 locus, resulting in continuous expression of RFP red
fluorescence. Upon the expression of Cre recombinase in the presence of tamoxifen
(TAM),

GFP

is

expressed

with

green

fluorescence

indicating

successful

recombination. Since Cre recombinase can only be induced in K14-expressing cells,
the recombination is restricted to basal epidermal keratinocytes upon tamoxifen
treatment.
In this in vivo cutaneous wound healing model, 1 cm- wounds were generated
using the proprietary compound DXB, which only removes the epidermis of the skin
while leaving the dermis intact. This approach specifically examined roles of ΔNp63
in epidermal cells during re-epithelization. After wounding, tamoxifen (ΔNp63Δ/Δ,
R∆/∆, K14CreER+ or ΔNp63Δ/Δ for short) and ethanol (ΔNp63fl/fl, RM/M, K14CreER+ or
ΔNp63fl/fl for short) were applied to the wound sites. The skins were collected after 1,
4, and 8 days post-wounding (Figure 10A). The recombination was confirmed by the
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expression of GFP at day 4 post-wounding in tamoxifen-treated group (ΔNp63Δ/Δ),
but not in control ethanol-treated group (ΔNp63fl/fl) (Figure 10B). Skin samples were
processed and stained with hematoxylin and eosin (H&E). Then, wound size was
measured at each time point. The results showed that the ΔNp63Δ/Δ mice
demonstrated defects in wound healing compared to the control group. While the
control mice had completely re-epithelialized the wound sites after 4 days postwounding, the ΔNp63Δ/Δ mice still maintained unhealed wounds even after 8 days
post-wounding (Figure 10C-D). A staining of K5, a cytokeratin marker for basal cells
and GFP in the skin sections confirmed the delay in re-establishing the epithelial
sheets at the wound sites on ΔNp63Δ/Δ mice (Figure 10E), suggesting that the loss of
ΔNp63 in basal keratinocytes prevents wound repair process.
Next, the skin sections were stained for K14, another marker for basal cells,
and Ki67, a marker for cell proliferation, to determine if the ablation of ΔNp63 in
keratinocytes reduced cell proliferation which potentially contributed to the delay in
wound healing. Surprisingly, ΔNp63Δ/Δ keratinocytes showed no significant
difference in proliferation compared to ΔNp63fl/fl cells at day 1 post-wounding.
However, while ΔNp63fl/fl keratinocytes significantly reduced proliferative capacity
after 4 and 8 days post-wounding when the re-epithelialization process was
completed, ΔNp63Δ/Δ keratinocytes maintained high proliferation rate even after 8
days post-wounding when the wounds still remained open (Figure 11A-B). These
data suggest that ΔNp63 depletion in basal keratinocytes delays wound healing
process, but not due to defects in cell proliferation.
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Figure 10: ΔNp63 loss delays epithelial wound healing in vivo. A, Experimental
design for in vivo cutaneous wound healing model. ΔNp63fl/fl, RosaM/M, K14CreER+
mice were treated topically with DXB compound to create 1-cm wounds and induced
recombination constrained to the epidermis by tamoxifen for 3 consecutive days.
Wound sites were assessed on days 1, 4, and 8 post-wounding. B, Representative
fluorescent images of frozen skin sections from ΔNp63fl/fl, RM/M, K14CreER+ (Left) and
ΔNp63Δ/Δ, R∆/∆, K14CreER+ (Right) for TdTomato (Red), GFP (Green) and Nuclear
(Blue). C, H&E sections of ΔNp63fl/fl, RM/M, K14CreER+ and ΔNp63Δ/Δ, R∆/∆, K14CreER+
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skin collected on days 1, 4, and 8 after wounding. The dotted line marks the
epidermis-dermis border, and the box marks the wound site. D, Quantification of
wound size on days 1, 4, and 8 post-wounding. n = 3, Asterisks indicate statistical
significance, p < 0.05 versus ΔNp63fl/fl, RM/M, K14CreER+ mice. E, Double
immunofluorescence staining of ΔNp63fl/fl, RM/M, K14CreER+ and ΔNp63Δ/Δ, R∆/∆,
K14CreER+ skin sections on days 1, 4, and 8 after wounding for K5 (red) and GFP
(green). Figure 9A-D was prepared by Ramon Flores González, M.D., Ph.D.
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Figure 11: ΔNp63-deficient basal keratinocytes maintain high proliferative
capacity during wound healing. A, Double immunofluorescence staining of
ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, and 8 after wounding for K14
(green) and Ki67 (red). B, Quantification of Ki67-positive cells on days 1, 4, and 8
post-wounding. n = 3, Asterisks indicate statistical significance, p< 0.0002 versus
ΔNp63fl/fl
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3.2.3 The depletion of ΔNp63 induces an EMT during wound healing process
in vivo
Since ΔNp63-deficient keratinocytes do not exhibit defects in cell proliferation,
another mechanism might account for the impaired re-epithelialization process
during wound repair. Keratinocytes at the migratory front have been shown to
undergo a “partial EMT” in which epidermal cells gain motility while maintaining
loose cell-cell contact necessary for re-epithelialization of wounded sites (47, 74).
The fact that a “partial” EMT is a key feature during wound healing prompted a
question on whether a complete “irreversible” EMT induced by depletion of ΔNp63
during wound healing would interfere with the process. In order to address this
question, skin sections from both ΔNp63fl/fl and ΔNp63Δ/Δ mice were stained for Ecadherin and Vimentin. Similar to in vitro data, the loss of ΔNp63 indicated by GFP
expression in epidermal cells in ΔNp63Δ/Δ mice decreased expression of E-cadherin
in both day 4 and 8 after wounding (Figure 12A). Interestingly, while Vimentin was
induced in skin samples from both ΔNp63fl/fl and ΔNp63Δ/Δ mice at day 1 postwounding, only ΔNp63Δ/Δ epidermal cells maintained expression of Vimentin until 8
days after wound induction (Figure 12B).

This suggests that ΔNp63-depleted

epidermal cells undergo a more complete EMT, further transitioning into a
mesenchymal state.
To further confirm the induction of an EMT upon the depletion of ΔNp63
during wound repair process, skin sections from both ΔNp63fl/fl and ΔNp63Δ/Δ mice
were stained for known EMT-related transcription factors, Twist1 and Lef1. The
results demonstrated that Twist1 and Lef1 were up-regulated epidermal cells from
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ΔNp63Δ/Δ mice since day 4 post-wounding, while cells from ΔNp63fl/fl mice showed
undetectable expression of these two transcription factors even at day 1 after
wounding (Figure 13A-B). In summary, these data show that the loss of ΔNp63 in
epidermal cells promotes an “irreversible” EMT via activation of transcription factors
Twist1 and Lef1, which prevents the wound healing process.

3.2.4 ΔNp63 modulates EMT in epidermal cells via regulating expression of
Twist1 and Lef1
To identify underlying mechanisms in which ΔNp63 regulates EMT in basal
keratinocytes, ΔNp63-/- cells were knocked down of Twist1 and Lef1 using siRNAs,
and assessed for migration and invasion capacity. Western blot data confirmed
successful down-regulation of Twist1 and Lef1 (Figure 14A). Similar to data obtained
in previous experiments, ΔNp63-/- KCs transfected with non-targeting siRNA control
(NT) showed significant increase in both migration and invasion compared to WT
KCs. The knockdown of either Twist1 or Lef1 in ΔNp63-/- KCs rescued the
phenotype, decreasing number of migrating and invading cells through the
membranes (Figure 14B-C). However, the rescue effects were partial compared to
WT KCs. This indicates that Twist1 and Lef1 partially contribute to the increased
invasiveness of basal epidermal cells upon depletion of ΔNp63.
As shown in Figure 8B, protein levels of both Twist1 and Lef1 were upregulated in ΔNp63-/- KCs. In addition, a significant induction of Twist1 and Lef1 at
mRNA level was observed in both human and mouse keratinocytes when ΔNp63
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Figure 12: ΔNp63-depleted keratinocytes display a mesenchymal phenotype
during wound healing in vivo. A-B, Double immunofluorescence staining of
ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, and 8 post-wounding for Ecadherin (red) and GFP (green) (A), or Vimentin (red) and GFP (green) (B)
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Figure 13: ΔNp63-depleted keratinocytes undergo a complete EMT during
wound healing in vivo. A-B, Immunohistochemical staining of ΔNp63fl/fl and
ΔNp63Δ/Δ skin sections at day 1, 4, and 8 after wounding for Twist1 (A) and Lef1 (B)
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was depleted (Figure 14D-E), suggesting Twist1 and Lef1 might function
downstream of ΔNp63 in regulating EMT. To decide if there was a direct
transcriptional repression of ΔNp63 on Twist1 and Lef1 expression, chromatin
immunoprecipitation of ΔNp63 on the promoters of Twist1 and Lef1 was performed
in WT and ΔNp63-/- KCs. However, the results failed to demonstrate enrichment of
ΔNp63 on Twist1 and Lef1 promoters (Figure 14F-G), indicating no direct binding
was observed. Taken together, these findings identified Twist1 and Lef1 as indirect
downstream targets of ΔNp63 in regulating EMT. Other ΔNp63-mediated pathways
might be involved in controlling expression of these two transcription factors.

67

Figure 14: ΔNp63 modulates EMT via regulating expression of Twist1 and
Lef1. A, Western blot analysis for knockdown efficiency of either Twist1 or Lef1 in
ΔNp63-/- KCs. B-C, Boyden chamber assay for migration (B) and invasion (C) of WT
KCs and ΔNp63-/- KCs transfected with either siTwist1 or siLef1. Asterisks indicate
statistical significance, p ≤ 0.0006 versus WT KCs. D-E, qRT-PCR of human and
murine Twist1 mRNA (D) and Lef1 mRNA (E) in NHEK-WT, NHEK-shΔNp63, WT
KCs and ΔNp63-/- KCs. Asterisks indicate statistical significance, p < 0.0005 versus
NHEK-WT or WT KCs. F-G, qRT-PCR of chromatin immunoprecipitation of ΔNp63
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binding to promoters of human Twist1 (F) and Lef1 (G) genes in NHEK-WT and
NHEK-shΔNp63. NSBS, non-specific binding sites.
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3.2.5 miR-98-3p and miR-34a-5p modulate EMT in keratinocytes via Twist1
and Lef1
Since Twist1 and Lef1 are not direct targets of ΔNp63 during EMT induction,
other ΔNp63-mediated pathways may account for the regulation of ΔNp63 on these
two factors at protein level. MicroRNAs have been intensively shown to play
essential roles in post-transcriptional regulation of EMT-associated transcription
factors, including Twist1 and Lef1 (60, 61). Moreover, ΔNp63 is involved in
microRNA biogenesis machinery through direct transcriptional activation of DGCR8
(7), suggesting that ΔNp63 might regulate Twist1 and Lef1 expression through
microRNAs. Utilizing published RNA and microRNA profiles of WT and ΔNp63-/- KCs
from the Flores lab (7), a microRNA-mRNA functional pair analysis was performed to
identify up-regulated microRNAs that potentially regulate Twist1 and Lef1 expression
upon ΔNp63 depletion. While the analysis identified several candidate microRNAs
regulating Zeb1/2, only miR-98-3p (miR-98) and miR-34a-5p (miR-34a) were linked
to Twist1 and Lef1, respectively (Figure 15A). Next, expression validation results
showed that both miR-98 and miR-34a were down-regulated upon the ablation of
ΔNp63 in both mouse and human keratinocytes (Figure 15B-C). Furthermore, the
overexpression of miR-98 or miR-34a in ΔNp63-/- KCs reduced expression of Twist1
or Lef1, respectively (Figure 16A-D). The reduction in Twist1 and Lef1 level in
ΔNp63-/- KCs led to significant decrease in migration and invasion capacity of
ΔNp63-/- KCs compared to WT KCs (Figure 16E-F). In summary, ΔNp63 represses
expression of Twist1 and Lef1 via miR-98 and miR-34a respectively, to prevent EMT
in epidermal cells.
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Overall, these data elucidate inhibitory effects of ΔNp63 on EMT in epidermal
cells through regulating Twist1 and Lef1. Thus, the depletion of ΔNp63 in basal
keratinocytes during wound healing elicits an irreversible EMT, which in turn delays
wound repair process in vivo.
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Figure 15: miR-98-3p and miR-34a inhibit expression of Twist1 and Lef1,
respectively in keratinocytes. A, MicroRNA-RNA pair analysis for genes
associated with EMT upon the depletion of ΔNp63 in KCs. B-C, Taqman qRT-PCR
of miR-98-3p (miR-98) (B) and miR-34a-5p (miR-34a) (C) in NHEK-WT, NHEKshΔNp63, WT KCs and ΔNp63-/- KCs. Asterisks indicate statistical significance, p ≤
0.0001 versu NHEK-WT or ΔNp63-/- KCs.
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Figure 16: ΔNp63 represses cell migration and invasion via miR-98/Twist1 and
miR-34a/Lef1 axes. A-B, Taqman qRT-PCR of miR-98 (D) and miR-34a (E) in
ΔNp63-/- KCs overexpressing either miR-98 (D) or miR-34a (E). Asterisks indicate
statistical significance, p < 0.0001 versus empty vector (EV). C-D, Western blot
analysis of Twist1 (F) and Lef1 (G) expression levels in ΔNp63-/- KCs
overexpressing either miR-98 (F) or miR-34a (G). E-F, Boyden chamber assay for
migration (H) and invasion (I) assay of WT KCs and ΔNp63-/- KCs infected with
either miR-98, miR-34a, or empty vector. Asterisks indicate statistical significance, p
< 0.0006 versus empty vector (EV).
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Chapter 4: Pleiotropic roles of ∆Np63 in tumor development and progression
Content of this chapter is based on the following article:


Hussein Abbas*, Ngoc Bui*, Kimal Rajapakshe, Justin Wong, Preethi Gunaratne,
Kenneth Y. Tsai, Cristian Coarfa and Elsa R. Flores. Distinct TP63 isoforms
transcriptional signatures predict tumor progression and clinical outcomes.
Cancer Research (2018) 78(2), 451–62. *co-first authors
Copyright permission is not required since Cancer Research journal policy states
“Authors of articles published in AACR journals are permitted to use their article
or parts of their article in the following ways without requesting permission from
the AACR.”

4.1 Introduction and rationale
Even though the contributions of p63 have been described in multiple
cancers, its transcriptional roles in tumor development and progression are
perplexing due to the existence of several isoforms and their variable expression in
different types of tissues, as well as their complex interaction with each other and
with p53 (1, 20, 22, 25, 27). While TAp63 has been demonstrated as a suppressor of
tumorigenesis and metastasis in various cancers, functions of ΔNp63 in cancers
remain controversial. Complex roles of ΔNp63 have been observed in different types
and stages of cancers (15, 22, 25, 27, 120, 133, 134). Therefore, a global approach
is essential to provide a comprehensive insight into tissue-specific roles of the genes
regulated by ΔNp63 in cancer development and progression, which may ultimately
explain ΔNp63-associated opposing phenotypes in different cancers. By applying an
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integrative model for TAp63 and ΔNp63 signatures from mice into The Cancer
Genome Atlas (TCGA) derived signatures, we aimed to decipher tissue-specific
transcriptional activities of TAp63 and ΔNp63 across multiple cancers in order to
propose these signatures as potential prediction tools to further stratifying patients
into groups that can benefit from p63-isoform specific targeted therapy (25, 27).

4.2 Results
4.2.1 Gene Set Enrichment Analysis (GSEA) and signature activity reveal
pleiotropic roles of TAp63 and ΔNp63 in tumor development and
progression
TAp63 and ΔNp63 RNA signatures were generated from primary TAp63-/KCs (135) and ΔNp63-/- KCs (7). Then, these signatures were used to analyze for
p63 isoform-specific transcriptomes across multiple cancers in TCGA database.
Since different biological processes and pathways are activated during cancer
development and progression, distinct RNA signatures for tumor development and
progression were derived by comparing the expression profile of tumors to normal
tissues and expression profile of high stage/grade tumors to low stage/grade tumors,
respectively (135).

Next, the TAp63- and ΔNp63-specific transcriptomes were

characterized for enrichment in 17 tumor development and 27 tumor progression
signatures by employing the GSEA algorithm (136). Identification of putative tumor
suppressor and oncogene activities of p63 isoforms in cancer development and
progression was based on significance, directionality, and enrichment concordance.
Specifically, when both upregulated and downregulated tumor-associated signature
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genes are significantly enriched in concordant direction (positive normalized
enrichment scores (NES) for upregulated genes, and negative NES for
downregulated genes) with TAp63-/- or ΔNp63-/- signatures, this suggests a
concordance with the TAp63 or ΔNp63-deficient genotypes, thus a potential tumor
suppressor activity. Alternatively, discordant enrichment in TAp63-/- or ΔNp63-/signatures suggests a predominant wildtype phenotype, and hence a potentially
corresponding oncogenic activity. Based on this approach, we then identified p63
isoforms-derived signatures to measure corresponding transcriptional activity among
patients and across stages, and to assess for survival (Figure 17A).
Interestingly, TAp63 consistently exhibited a tumor suppressor pattern in 13
cancer development signatures and 5 progression signatures, while ΔNp63
exhibited a pleiotropic role in tumorigenesis and cancer progression: an oncogenic
pattern in 7 development and 1 progression signatures, and a tumor suppressive
pattern in 3 development and 5 progression signatures (q<0.0001) (Figure 17B).

4.2.2 TAp63 and ΔNp63 signatures predict patient survival
To enable pan-cancer clinical assessment applications informed by TAp63
and ΔNp63 transcriptional activities, we refined TAp63 tumor suppressive and
ΔNp63 oncogenic signatures (135) based on a survival-predictive model dubbed
Pan Cancer Survival Signature (PCSSTAp63 and PCSSΔNp63, respectively). PCSSTAp63
activity significantly decreased across various Stages I to IV cancers, including
breast (BRCA), kidney clear cell (KIRC), and kidney papillary (KIRP), lung
adenocarcinoma (LUAD), and lung squamous cell (LUSC) carcinoma
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Figure 17: Tissue and stage-dependent activities of TAp63 and ∆Np63 in tumor
development

and

progression.

A,

Working

model

for

identification

of

transcriptional networks enriched in TCGA tumors. B, Summary of GSEA
concordant findings across in cancer development and cancer progression
signatures. Reproduced with permission from Abbas*, Bui* et al., Cancer Research
(2018) 78(2), 451–62
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(ANOVA<0.0001-0.032), exhibiting a consistent tumor suppressor pattern (Figure
18A). PCSSΔNp63 activity, on the other hand, increased significantly from Stage I to
IV in BRCA and LUAD (ANOVA<0.0001), patterning an oncogenic role (Figure 18B).
Strikingly, patients with increased activity of PCSSTAp63 and PCSSΔNp63 had
significantly better and worse overall survival, respectively, within stages and across
all patients (p<0.0001-0.038) (Figure 18C-D). Both PCSSTAp63 and PCSSΔNp63
signatures showed enrichments in pathways involved in metabolism and cell cycle
(Figure 18E-F). Taken together, these data demonstrated tumor-suppressive roles of
TAp63 and tumor-promoting roles of ∆Np63 in majority of cancers analyzed in
TCGA. More interestingly, these signatures can further be utilized to predict patient
survival.

4.2.3 ΔNp63 plays a pleiotropic role as a tumor suppressor or oncogene
during tumor development
Since ∆Np63 exhibits functional pleiotropic roles in tumor development where
it exerts oncogenic activities in some cancers and tumor suppressive activities in
others, the basal expression level of ∆Np63 may vary among different cancers.
Based on the TCGA analysis across multiple cancers (Figure 17B), ∆Np63 was
shown to function as an oncogene in breast cancer (BRCA) and lung squamous cell
carcinoma (LUSC) while displaying tumor suppressive functions in kidney clear cell
(KIRC). The expression of ∆Np63 was examined in cell lines derived from these
cancers, including MCF10-CA1D (BRCA), HCC95 (LUSC) and Caki-1 (KIRC).
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Figure 18: TAp63 and ΔNp63 signatures predict patient survival. A-B, Heatmap
of the activity of PCSSTAp63 (A) and PCSSΔNp63 (B) across different stages of
tumorigenesis. C-D, Dot plot of the survival analysis of different tumors with respect
to PCSSTAp63 (C) and PCSSΔNp63 (D). E-F, -Log10(p-value) of pathways enriched in
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PCSSTAp63 (E) and PCSSΔNp63 signatures (F). Reproduced with permission from
Abbas*, Bui* et al., Cancer Research (2018) 78(2), 451–62
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Interestingly, ∆Np63 is highly expressed in MCF10-CA1D and HCC95 while
remaining undetectable in Caki-1 cells (Figure 19A). This observation is in
accordance with respective roles of ∆Np63 in those tumor types. Next, I asked if
manipulation of ∆Np63 level in these cells would result in opposing effects on their
oncogenic activities. Thus, ∆Np63 was knocked down using specific si∆Np63 in
MCF10-CA1D and HCC95 and overexpressed in Caki-1 cells (Figure 19B). ∆Np63α
was used for the overexpression as it is the predominant isoform of ∆Np63 found in
majority of cancers (18).
Knockdown of ΔNp63 in MCF10-CA1D breast cancer cells reduced
proliferation and soft agar colony formation (Figure 20A-D). In HCC95 LUAD cells,
knockdown of ∆Np63 decreased soft agar colony formation but not proliferation
(Figure 20E-H), suggesting oncogenic functions of ∆Np63 in BRCA and LUAD. To
assess tumor suppressor activities of ΔNp63, ΔNp63α was overexpressed in Caki-1
cells, and while no significant difference in proliferation was observed (Figure 20J-I),
the number of colonies on soft agar decreased by 2-fold compared to control (Figure
20K-L), indicating tumor suppressive activities of ΔNp63 in KIRC. Taken together,
these data further support that ∆Np63 plays a pleiotropic role depending on tissues
of origin.
4.2.4 ΔNp63

activates

an

oncogenic

program

through

transcriptional

regulation of its downstream target, Lef1
To identify the pleiotropic mechanism exerted by ΔNp63 in tumorigenesis, our
TCGA derived signatures were overlapped with previously published human ∆Np63
Chip-Seq data (137), which revealed enrichment for EMT genes. Next,
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Figure 19: Differential expression of ΔNp63 in MCF10-CA1D, HCC95 and Caki-1
cells. A, Western blot analysis for ΔNp63 expression in MCF10-CA1D, HCC95 and
Caki-1 cells. NHEK-WT and NHEK-shΔNp63 were used as positive and negative
control for ΔNp63 expression. Actin was used as internal loading control. B, Western
blot analysis for either ΔNp63 knockdown efficiency in MCF10-CA1D and HCC95
treated with either siC or siΔNp63, or ΔNp63 overexpression in Caki-1 cells treated
with either empty vector (EV) or ΔNp63α-overexpressing plasmid (ΔNp63α).
Reproduced with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2),
451–62
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Figure 20: ΔNp63 plays a pleiotropic role as a tumor suppressor or oncogene.
A-D, E-F,I-J, Quantification and fluorescence representative images of EdU (green)
incorporation MCF10-CA1D (A-B), HCC95 (E-F) and Caki-1 (I-J) cell lines. C-D,
G-H, K-L, Quantification and bright field representative images of anchorageindependent colony formation of MCF10-CA1D (C-D), HCC95 (G-H) and Caki-1 (KL) cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. Asterisks
indicate statistical significance, p < 0.005 versus siRNA scramble control (siC) or
empty vector (EV), two-tailed t test. Reproduced with permission from Abbas*, Bui*
et al., Cancer Research (2018) 78(2), 451–62
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hypergeometric analysis was conducted to identify transcription factors that regulate
these EMT genes and overlapped with ΔNp63 keratinocyte signatures. Several Lef1
targets (INHBA, USP2, COL5A1, BMP1, PMEPA1) were identified to be highly
significant (p=0.0009). Therefore, to assess whether ∆Np63 exerts its oncogenic
functions through Lef1, Lef1 expression at mRNA and protein level in MCF10-CA1D
and HCC95 cell lines was determined upon ∆Np63 knockdown. Indeed, Lef1
expression decreased (Figure 21A-B), indicating that Lef1 is downstream of ΔNp63.
More interestingly, depletion of Lef1 using siRNAs in both MCF10-CA1D and HCC95
cell lines (Figure 21C) reduced colony formation in soft agar similar to what was
observed when ΔNp63 was knocked down in these cells (Figure 21D-G). In addition,
overexpressing Lef1 in ΔNp63-depleted cells (Figure 22A) significantly increased
MCF10-CA1D and HCC95 colony formation (Figure 22B-E), and MCF10-CA1D cell
proliferation (Figure 22F-G), but not HCC95 proliferation (Figure 22H-I). Together,
these data demonstrated that ∆Np63 functions as an oncogene via regulating Lef1 in
MCF10-CA1D BRCA and HCC95 LUSC cells.

4.2.5 Lef1 is a downstream target of ΔNp63, but fails to exert tumor
suppressive functions of ΔNp63 in Caki-1 cells
In Caki-1 cells where ΔNp63 functions as a tumor suppressor, the
overexpression of ∆Np63 upregulated Lef1 mRNA and protein expression (Figure
23A-B), which further confirmed that ΔNp63 regulates Lef1 expression. Then, to
assess whether the tumor suppressive role of ∆Np63 functions through Lef1, Lef1
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Figure 21: Lef1 is a downstream target of ΔNp63 in MCF10-CA1D and HCC95.
A, qRT-PCR for Lef1 in MCF10-CA1D and HCC95 cells expressing either siC or
siΔNp63. Asterisks indicate statistical significance, p < 0.005 versus siC, two-tailed t
test. B-C, Western blot analysis for: Lef1 expression in MCF10-CA1D and HCC95
cells expressing either siC or siΔNp63 (B) or in MCF10-CA1D and HCC95 cells
treated with siC, siLef1-1 or siLef1-2 (C). Actin was used as a loading control. D-G,
Quantification and bright field representative images of anchorage-independent
colony formation of indicated cell lines in soft agar assay (per 10X field). Data are
mean ± SD, n = 3. Asterisks indicate statistical significance, p < 0.005 versus siC or
siΔNp63, two-tailed t test. Reproduced with permission from Abbas*, Bui* et al.,
Cancer Research (2018) 78(2), 451–62
86
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Figure 22: ΔNp63 exerts it oncogenic activities via Lef1 in MCF10-CA1D and
HCC95 cells. A, Western blot analysis for ΔNp63 and Lef1 expression in MCF10CA1D and HCC95 cells treated with siΔNp63 and Lef1-overexpressing plasmid
(Lef1). Actin was used as internal loading control. B-E, Quantification and bright field
representative images of anchorage-independent colony formation of indicated cell
lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. Asterisks
indicate statistical significance, p < 0.005 versus siC or siΔNp63, two-tailed t test. FI, Quantification and fluorescence representative images of

EdU (green)

incorporation of indicated cell lines. Data are mean ± SD, n = 3. Asterisks indicate
statistical significance, p < 0.05 versus siC or siΔNp63, two-tailed t test. Reproduced
with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2), 451–62
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was overexpressed in Caki-1 cells, resulting in a non-statistically significant
decrease in soft agar colony formation (Figure 23C-E). However, when Lef1 was
knocked down in Caki-1 cells overexpressing ΔNp63α (Figure 23F), no significant
difference was observed in cell proliferation and colony formation (Figure 23G-J),
suggesting the involvement of other factors than Lef1 in the tumor suppressive roles
of ΔNp63. Hence, ∆Np63 regulation of Lef1 dictates its oncogenic roles in different
tissues while the tumor suppressor pathways of ∆Np63 are not yet identified.

4.2.6 ΔNp63-regulated transcriptional activities are lost in higher stages and
can predict survival of BLCA, KIRC, KIRP and LGG
GSEA analysis revealed a suppressive role for ΔNp63 in the progression of 4
tumors: bladder cancer (BLCA), KIRC, KIRP and low grade glioma (LGG). To
explore the role of ΔNp63 in tumor progression, ΔNp63-regulated genes that were
enriched in cancer progression signatures and the corresponding isoform signature
were identified, hereafter dubbed ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG
(Figure 24A-B). Interestingly, high grade/stage BLCA, KIRC, KIRP and LGG had
significantly lower activities of their corresponding ΔNp63-driven signature compared
to low grade/stage tumors (p<0.0001), suggesting that higher grade/stage tumors
lose ΔNp63 activities upon progression (Figure 24C). Further, KIRC (p<0.0001) and
LGG (p<0.0001) patients with higher corresponding ΔNp63 activity had significantly
better survival than patients with lower activity (Figure 24D). Association between
activity and survival was also evident within the same grade/stage of tumors (Figure
24E). This is of particular importance as it suggests that there is significant
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Figure 23: Lef1 is a downstream target of ΔNp63 in Caki-1. A, qRT-PCR for Lef1
in Caki-1 cells expressing either empty vector (EV) or ΔNp63α-overexpressing
plasmid (ΔNp63α). Asterisks indicate statistical significance, p < 0.005 two-tailed t
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test. B, Western blot analysis for Lef1 in Caki-1 cells expressing either empty vector
(EV) or ΔNp63α-overexpressing plasmid (ΔNp63α). Actin was used as internal
loading control. C, Western blot analysis for Lef1 overexpression efficiency in Caki-1
cells expressing either with empty vector (EV) or ΔNp63α-overexpressing plasmid
(ΔNp63α). Actin was used as internal loading control. D-E, Quantification and bright
field representative images of anchorage-independent colony formation of indicated
cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. F, Western
blot analysis for ΔNp63 and Lef1 expression in Caki-1 cells treated with ΔNp63αoverexpressing plasmid (ΔNp63α) and siLef1. Actin was used as internal loading
control. G-H, Quantification and fluorescence representative images of EdU (green)
incorporation of indicated cell lines. Data are mean ± SD, n = 3. I-J, Quantification
and bright field representative images of anchorage-independent colony formation of
indicated cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3.
Asterisks indicate statistical significance, p < 0.0005 versus EV, two-tailed t test.
Reproduced with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2),
451–62
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heterogeneity in the activity of ΔNp63 within high stages of KIRC, KIRP and LGG
that may warrant different therapy.

4.2.7 Pluripotency potential, EMT and ECM remodeling in high stage tumors
are modulated by ΔNp63 signatures
In the ΔNp63-derived signatures, there were 2 genes (CTHRC1 and COL5A1
both are major ECM constituents) and 14 pathways that were common among
ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG (135). The highest enrichments in
ΔNp63 signatures were developmental and extra cellular matrix (ECM) remodeling
pathways (Figure 25A) which are indicative of stem cell pluripotency, EMT, and
metastatic mechanisms. Therefore, we investigated whether previously published
stem cell, ECM and EMT signatures were enriched in high grade/stage tumors and
ΔNp63-/- keratinocytes. Interestingly, GSEA analyses identified a significant
enrichment of cancer invasive and primary stem cells (138, 139), mouse and human
embryonic stem cell signatures (140, 141), Nanog, Oct4 and Sox2 (NOS) targets
(140) and primary tumor and metastatic ECM signatures (142) in high grade/stage
tumors and ΔNp63-/- epidermal cells signatures (Figure 25B-C). In addition, a
significant enrichment of EMT in ΔNp63-/- keratinocytes and progression signatures
of BLCA, KIRC and KIRP was also observed (Figure 25D), which is consistent with
our observations on the induction of EMT upon depletion of ΔNp63.
In summary, the suppressive activity of ΔNp63 in tumor progression is
consistent with previous reports indicating that ΔNp63 promotes differentiation of
epithelial tissues and that loss of ΔNp63 leads to EMT and pluripotency (7, 143).
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Figure 24: Tumor suppressor activity of ΔNp63 in cancer progression. A,
Circos plots of the overlap and expression of ΔNp63 signatures with progression
signatures of BLCA, KIRC, KIRP and LGG. B, Normalized enrichment score (NES)
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of upregulated and downregulated cancer progression signatures in TAp63-/- and
ΔNp63-/- signatures. C, Activity score of ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and
ΔNp63LGG in corresponding cancer patients at high and low grade/stages. D, KaplanMeier survival of BLCA, KIRC, KIRP and LGG patients with respect to the
corresponding ΔNp63 signature activity. E, Kaplan-Meier survival within Stage IV
KIRC, and G2 and G3 LGG patients with respect to ΔNp63KIRC and ΔNp63LGG
activities, respectively. Number of cases in each survival group is listed between
parenthesis where indicated. Reproduced with permission from Abbas*, Bui* et al.,
Cancer Research (2018) 78(2), 451–62
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The progression of these tumors entails loss of ΔNp63 transcriptional activities,
which leads to increased stem cell pluripotency, ECM remodeling, and EMT, leading
to tumor progression and metastasis (Figure 25E). These findings identify patients
within different stages that could benefit from treatments that specifically target these
pathways.
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Figure 25: Enrichment of pluripotency, ECM and EMT in ΔNp63 driven
progression signatures. A, Log10(p-value) of pathways enriched in ΔNp63BLCA,
ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG. B-D, Normalized enrichment scores (NES) of
bladder cancer (BLCA), kidney clear cell (KIRC), kidney papillary (KIRP) and low
grade glioma (LGG) progression and ΔNp63-/- signatures in (B) known stem cells
and pluripotency, (C) ECM and (D) EMT signatures. E, Suggested model for ΔNp63
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to suppress tumor progression via modulation of EMT, ECM, pluripotency and cell
cycle activity. Reproduced with permission from Abbas*, Bui* et al., Cancer
Research (2018) 78(2), 451–62
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5. CHAPTER 5: DYNAMIC REGULATION OF ∆NP63 IN BREAST CANCER
PROGRESSION AND METASTASIS
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Chapter 5: Dynamic regulation of ∆Np63 during breast cancer progression and
metastasis

5.1 Introduction and Rationale
Since the discovery of different p63 isoforms with distinct physiological and
pathological functions, ∆Np63 has been shown by numerous studies to exert
oncogenic activities in cancers (25-27). This notion mostly arose from the fact that
∆Np63 is found to be highly expressed in primary tumors and metastases of multiple
cancers (144-146). In addition, several studies have reported anti-tumor effects
when ∆Np63 was depleted in the primary tumors (25, 27). Inhibitory effects of ∆Np63
on EMT and potentially metastasis have also been documented, which is in contrast
to its oncogenic roles observed in primary tumors, as discussed in details in section
1.3.4 and 1.4.2. However, these studies mainly focused on either in vitro
characterization or snapshot events of the multistep process of metastatic cascade,
yet failed to investigate contributions of ∆Np63 from the establishment of primary
tumors to the formation of distant metastases in vivo. Of note, the loss of ΔNp63 in
epithelial-like bladder cancer cells promotes EMT and enhance invasion, while the
induction of ΔNp63 in mesenchymal-like bladder cancer cells triggers MET and
suppresses cancer cell invasion (31), suggesting a dynamic regulation of ∆Np63
during EMT and metastasis. Moreover, we have recently demonstrated pleiotropic
functions of ∆Np63 during tumor development and progression using a global
approach on various types and stages of cancers (135). Together, these opposing
findings suggest a more intricate involvement of ∆Np63 during cancer progression
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and metastasis. Perhaps, ∆Np63 has a two-faceted role in cancer progression and
metastasis, which is similar to many important pathways in cancers such as TGFβ
signaling. Thus, I hypothesize that while ∆Np63 is required for primary tumor growth,
the loss of ΔNp63 in tumor cells at primary sites promote the dissemination of tumor
cells into circulation, whereas ΔNp63 expression is essential for circulating tumor
cells (CTCs) to colonize and form macro-metastases at distant organs (Figure 26).
More importantly, the identification of upstream regulators of ΔNp63 during this
process will propose potential biomarkers and treatments for metastatic cancers.
From our pan-cancer analyses using TCGA, ΔNp63 showed oncogenic
activities in the development of breast cancer, whereas we did not obtain significant
data for the progression of this cancer. Given that the roles of ΔNp63 in breast
cancer remain very controversial due to conflicting observations from different
studies, I aimed to decipher the dynamic regulation of ΔNp63 in an in vivo breast
cancer model in order to ultimately provide a comprehensive insight into the
contribution of this isoform from the establishment of primary breast tumors to
metastatic dissemination to distant lungs.
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Figure 26: Proposed working model for the dynamic regulation of ΔNp63 in
cancer progression and metastasis. At primary tumors, ΔNp63 is highly
expressed and required for tumor growth. In invading tumor cells, the loss of ΔNp63
promotes the dissemination of tumor cells into circulation. At distant sites, arrested
circulating tumor cells (CTCs) re-express ΔNp63 to colonize and form macrometastases at distant organs

5.2 Results
5.2.1 Clinical correlation between ΔNp63 expression and breast cancer
progression
First, we asked if there is any correlation between ΔNp63 and breast cancer
patient survival reported in TCGA database. Interestingly, low expression of ΔNp63
correlates with worse survival in patients with Stage III breast cancer (Figure 27A-C),
connecting the loss of ΔNp63 in advanced stage-primary tumors with poor
prognosis. In accordance with this result, immunostaining for ΔNp63 expression in
breast cancer tissue microarrays (TMA) with a spectrum of different stages of breast
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cancer revealed a significantly decreased expression of ΔNp63 in invasive breast
cancer samples (Figure 27D-E). In another breast cancer TMA with primary tumors
and corresponding lymph node metastases, there is a positive correlation for
expression level of ΔNp63 in primary tumors and their matched metastases (referred
as a “pair of sample”) (Figure 28A). Next, in order to analyze more details into the
expression pattern of ΔNp63 in primary tumors and corresponding metastases, pairs
of samples were classified into four groups based on the intensity of ΔNp63 staining:
high ΔNp63 in both primary and metastases, low ΔNp63 in both primary and
metastases, high ΔNp63 in primary and low ΔNp63 in metastases, low ΔNp63 in
primary and high ΔNp63 in metastases. Interestingly, the pattern of high ΔNp63 in
both primary and metastases has the highest percentage of samples in all 3 stages
of breast cancer (Figure 28B). This observation is in accordance with the previous
reports on high expression of ΔNp63 in both primary tumors and metastases.
Strkingly, there is an increase in samples with pattern of low ΔNp63 in primary and
high ΔNp63 in metastases from stage IIA to IIIA, indicating an increasing loss of
ΔNp63 in primary tumors while the matched metastases still retained expression of
ΔNp63 when tumors progressed (Figure 28B). Together, these data point out the
clinical connection between decreased expression of ΔNp63 and tumor progression
in breast cancer.
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Figure 27: Low ΔNp63 expression in advanced breast cancer correlates with
worse patient survival. A-B, Kaplan-Meier survival within Stage III breast cancer
patients with respect to low and high expression of ΔNp63α (A), ΔNp63β (B) and
ΔNp63γ (C). D, Immunohistochemistry staining for ΔNp63 in breast cancer tissue
microarray. E, Quantification of ΔNp63 expression (score) in breast cancer tissue
microarray. Score of each sample was determined by number of positive nuclei and
average staining intensity. Asterisks indicate statistical significance, p < 0.005.
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Figure 28: Expression level of ΔNp63 in human breast primary tumors and
corresponding lymph node metastases assessed by immunostaining for
ΔNp63 in human tissue microarray. A, Correlation plot for ΔNp63 expression
(score) in primary tumors and corresponding metastases. B, Distribution plot for ratio
of different ΔNp63 expression pattern between primary tumors and metastases at
different stages of breast cancer.
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5.2.2 Generating an inducible shRNA against ΔNp63 to conditionally knock
down ΔNp63 in vivo
A limitation of majority of the studies on ΔNp63 is the lack of shRNAs
specifically targeting ΔNp63 (shΔNp63). Due to the complexity at the TP63 locus,
most commercially available shRNAs target the DNA-binding domain (DBD) which is
common for both TAp63 and ΔNp63. Hence, specific shRNA for ΔNp63 targeting the
3’exon unique for the isoform only was designed. This shRNA was then cloned into
a doxycycline-inducible vector to express shRNA (Clontech). Next is the request for
a breast cancer cell line in which ΔNp63 could be manipulated in vivo to assess for
tumor establishment and metastatic formation. MCF10 progression model includes a
series of human mammary epithelial cell lines, malignant and non-malignant, which
were derived from the normal mammary epithelial cells MCF10A (10A) (147-149).
Among those cell lines, MCF10-DCIS (DCIS) cells formed comedo-like DCIS
structures, but exhibited very low spontaneous metastatic frequency to lungs and
livers when injected into mammary fat pads of nude mice. MCF10-CA1D (CA1D)
cells formed poorly differentiated tumors and have spontaneous metastases to lungs
and livers (Figure 29A). Therefore, DCIS cell were infected with inducible-shΔNp63
lentivirus to generate a stable cell line expressing the inducible-shΔNp63 (DCIS-ishΔNp63). In the presence of doxycycline (dox), ΔNp63 level was decreased after 3
days and started to come back two days after withdrawing dox from the media
(Figure 29B), indicating a successful manipulation of ΔNp63 using doxycycline in
vitro. These cells were next injected into nude mice to assess tumor and metastatic
formation.
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Figure 29: Generating MCF10-DCIS cell line expressing doxycycline-inducible
sh∆Np63. A, H&E sections of primary tumors, lung and liver metastases of
MCF10A, MCF10-DCIS and MCF10-CA1D cells injected into mammary fat pads of
nude mice. B, Western blot for ∆Np63 in MCF10DCIS-i-sh∆Np63 in the presence of
doxycycline. Actin was used as loading control.
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5.2.3 ΔNp63 promotes the establishment of primary tumors
The depletion of ΔNp63 by shΔNp63 upon doxycycline induction reduced cell
proliferation in vitro (Figure 30A-B), confirming tumor-promoting activities of ΔNp63
in primary tumors. In order to determine if ΔNp63 is essential for the establishment
of primary tumors of breast cancer cells in vivo, DCIS-i-shΔNp63 cells were cultured
in dox for 3 days prior to injection to mammary fat pads of nude mice. The mice were
then fed with either control or dox diet to induce expression of shΔNp63 in vivo. After
4 weeks, primary tumors were dissected out and measured for tumor volume (Figure
30C). The results demonstrated that cohort of mice on dox diet had significantly
smaller tumors compared to control diet mice (Figure 29D), suggesting that ΔNp63
is essential for the establishment of primary breast cancer in vivo.

5.2.4 ΔNp63 is required for lung extravasation and colonization of circulating
tumor cells
Since ΔNp63 promotes the formation of primary tumors, the next question is
whether ΔNp63 is also required for the establishment of distant metastases to the
lungs. There are two critical steps involved in the formation of overt metastatic
colonies at distant organs: extravasation and colonization. In order to determine
roles of ΔNp63 in extravasation of circulating tumor cells into the lungs,
DCIS-i-shΔNp63 cells were labeled with RFP using lentivirus expressing RFP. Next,
these cells were cultured in dox for 3 days. Control cells were cultured in media
without dox. The cells were then injected intravenously into nude mice via tail vein.
Mice injected with control cells were fed with control diet (group 1). Mice injected
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Figure 30: ∆Np63 promotes the establishment of primary tumors. A, Western
blot for ∆Np63 in DCIS-i-sh∆Np63 cells upon dox treatment. B, Growth curves for
DCIS-i-sh∆Np63 cells with or with dox treatment. C, Experimental design to
determine roles of ∆Np63 in primary tumors. D, Tumor volume (mm3) from nude
mice injected with DCIS-i-sh∆Np63 and fed with either control diet or dox diet.
Asterisk indicate statistical significance, p < 0.05 versus No dox diet . two-tailed t
test.
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with dox-treated cells were fed with either control diet (group 2) or dox diet (group 3).
After 48 hours, the lungs were collected and dissociated to get single cells for flow
cytometry assay to detect RFP-positive cells successfully extravasating into the
lungs (Figure 31A). The results showed that mice fed with dox diet (group 3) had a
decrease in number of RFP-positive cells in the lungs compared to mice fed with
control diet (group 1). Interestingly, mice injected with dox-treated cells but fed with
control diet (group 2) had similar percentage of RFP-positive cells to control group 1
(Figure 31B-C), indicating that ΔNp63 was essential for circulating cells to
extravasate into the lungs at early stage of lung colonization. A similar approach was
used to determine if ΔNp63 is also necessary for the formation of macro-metastases
in the lungs. In this experiment, the mice were aged till 8 weeks post-injection, then
the lungs were collected and quantified for number of metastatic nodules and micrometastases (Figure 32A). Similar to previous observation, group 1 and group 2 had
non-statistical significance in the number of both visible nodules and metastatic
colonies in the lungs, while group 3 exhibited a dramatic reduction in metastasis
formation (Figure 32B-E). Surprisingly, metastases in all three experimental groups
showed high expression of ΔNp63 (Figure 32F), suggesting that cells expressing
ΔNp63 might have greater advantage to colonize distant lungs. Taken together,
these in vivo data demonstrated that ΔNp63 is required for both extravasation and
colonization of tumor cells at distant lungs.
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Figure 31: ∆Np63 is required for lung extravasation of circulating tumor cells.
A, Experimental design to investigate roles of ∆Np63 in extravasation to the lungs of
tumor cells. B-C, Flow cytometry assay (B) and quantification (C) of the percentage
of RFP-positive cells extravasating to the lungs. Asterisk indicate statistical
significance, p < 0.05 versus group 2. ns, non-statistical significance. two-tailed t
test.
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Figure 32: ∆Np63 enhances lung colonization and formation of metastatic
colonies. A, Experimental design to investigate roles of ∆Np63 in lung colonization.
B-C, Bright field images of lung tissues (B) and quantification of visible lung nodules
per mouse (C). Asterisk indicate statistical significance, p < 0.0005 versus group 2.
ns, non-statistical significance. two-tailed t test. D-E, H&E sections of lung tissues
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(D) and quantification of micro- and macro-metastatic colonies per lung section per
mouse (E). Asterisk indicate statistical significance, p <0.0005 versus group 2 . ns,
non-statistical significance. two-tailed t test. F, Immunohistochemistry staining for
∆Np63 in metastatic colonies in the lungs.
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5.2.5 Dynamic regulation of ∆Np63 enhances metastatic colonization to the
lungs
My in vivo data have shown that ∆Np63 is necessary for the formation of both
primary tumors and metastases when we investigated each step of metastatic
cascade separately. The remaining important question is how ∆Np63 expression
affects the process of metastatic dissemination as a whole, from primary tumor
formation to lung colonization. In order to address this question, DCIS-i-sh∆Np63
cells were injected into mammary fat pads of nude mice, then waited for 2 weeks for
tumors become palpable. After that, the mice were fed either with control diet (group
1) or dox diet for 3 weeks. Then, one group of mice on dox diet was switched back
to control diet (group 2), while the other group was on dox diet (group 3) for another
3 weeks. After 3 more weeks, the mice were sacrificed for primary tumors and lungs
to assess metastatic frequency (Figure 33A). Consistent with our previous findings,
the depletion of ∆Np63 in established tumors also reduced tumor growth (Figure
33B). Primary tumors from group 3 showed lower expression of ∆Np63 and Ki67
compared to group 1 and 2, indicating that the loss of ∆Np63 decreased tumor cell
proliferation which led to reduced tumor growth (Figure 33C-D). Strikingly, mice on
dox diet for 3 weeks then control diet for 3 weeks (group 3) showed the highest
metastatic frequency among three groups. Interestingly, mice continuously fed with
dox diet for 6 weeks (group 3) had higher metastatic frequency than the control diet
group (group 1) (Figure 33E). In addition, metastases in the lungs from all three
groups were positive for ΔNp63 staining (Figure 33F), suggesting that a subset of
cells that managed to escape the knockdown effect of the shRNA or regain
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Figure 33: Dynamic regulation of ∆Np63 enhances metastatic colonization to
the lungs. A, Experimental design to investigate the dynamic regulation of ∆Np63 in
cancer metastasis. B, Tumor volume (mm3) of mice injected with DCIS-i-sh∆Np63
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cells and fed with different diet schedules. Asterisk indicate statistical significance, p
<0.05 versus group 1 or group 2. ns, non-statistical significance. two-tailed t test. C,
Immunohistochemistry for ∆Np63 and Ki67 in primary tumors. D, Western blot for
∆Np63 in lysates from primary tumors. Actin was used as loading control. E,
Metastatic frequency to the lungs. F, Immunohistochemistry for ∆Np63 in primary
tumors and lung metastases.
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expression of ∆Np63 were able to colonize the lungs. These data further revealed
that the loss of ΔNp63 in the primary tumors facilitates metastasis, whereas the reexpression of ΔNp63 in circulating cells is essential for the establishment of distant
metastases.

5.2.6 TGFβ signaling inhibits expression of ΔNp63 in breast cancer
Given that the dynamic regulation of ΔNp63 plays important roles in
metastatic dissemination, it is necessary to identify upstream regulators of ΔNp63 in
the process in order to propose potential targeted therapy and biomarkers that
connect ΔNp63 with breast cancer progression. TGFβ signaling has been shown to
have dual roles in breast cancer development and metastasis. In normal cells and
early stage tumors, TGFβ exerts its tumor suppressive functions to inhibit
tumorigenesis via inducing apoptosis and cell growth arrest. In contrast, in advanced
cancer, TGFβ functions as a pro-metastatic factor by inducing EMT and promoting
breast cancer cell migration and invasion, which ultimately favors metastatic
dissemination (150, 151). Interestingly, a recent study revealed that a constitutive
activation of TGFβ signaling promotes single cell invasion and intravasation in
primary tumors, but fails to facilitate tumor growth of distant metastases, whereas a
localize and reversible TGFβ signaling is required for bone metastatic dissemination
of breast cancer (107). This mechanism of action resembles our observations on
functions of ΔNp63 in multistep process of metastatic cascade, suggesting a
possible regulatory network connecting TGFβ signaling and ΔNp63.
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Figure 34: TGFβ signaling inhibits expression of ΔNp63 in breast cancer. A,
Bright field images of DCIS cells expressing shΔNp63 or treated with TGFβ. B-D,
Western blot for indicated antibodies in 10A, DCIS and CA1D cells treated with
TGFβ (B) or with TGFβ and LY2157299 (C) or with TGFβ and siSmad3 (D). Actin
was used as loading control.
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Indeed, in the presence of TGFβ, DCIS cells shared similar morphology to
ΔNp63-depleted cells (Figure 34A). Strikingly, ΔNp63 expression was dramatically
reduced in the presence of TGFβ in 10A, DCIS and CA1D cells. Increased
phosphorylation of Smad2/3 was also observed in all three cell lines (Figure 34B),
indicating that TGFβ may potentially inhibit ΔNp63 expression via Smad2/3
transcriptional activities. To further confirm the regulation of ΔNp63 by TGFβ
signaling, the cells were treated with LY2157299, an inhibitor of TGFβ-receptor I
(TGFβRI), to inactivate TGFβ signaling cascade. The results showed that the
inhibition of ΔNp63 expression by TGFβ was rescued in the presence of LY2157299
(Figure 34C). TGFβ signaling is transduced through either canonical Smaddependent

pathways

or

non-canonical

Smad-independent

pathways

(152).

Knockdown of Smad3 in 10A and DCIS cells prevented TGFβ-induced reduction of
ΔNp63 (Figure 34D), suggesting the connection between TGFβ and ΔNp63 through
Smad2/3 complex.

5.2.7 TGFβ-induced microRNAs regulate expression of ΔNp63
In order to determine whether there is a direct transcriptional repression of
Smad2/3 complex on the expression of ΔNp63, mRNA level of ΔNp63 upon TGFβ
induction was examined. Nevertheless, no significant reduction of ΔNp63 mRNA
was observed in the presence of TGFβ (Figure 35A), whereas its protein level was
dramatically decreased (Figure 35B). This suggests there may not be a direct
transcriptional regulation of Smad2/3 at the promoter of ΔNp63. Thus, the
involvement of other regulatory mechanisms may account for the regulation of
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ΔNp63 by TGFβ signaling. microRNAs have been intensively studied for their roles
in post-transcriptional regulation of gene expression. Crosstalk between TGFβ and
microRNA machinery have been reported in multiple cancers (153). Hence,
differential expressed microRNAs in DCIS cells upon TGFβ induction was profiled
using NanoString nCounter human microRNA platform. The results identified 74 upregulated microRNAs upon TGFβ treatment (Figure 35C). Then, these microRNAs
were merged with a list of microRNAs predicted to have binding sites to the 3’UTR of
TP63 gene by miRWalk. This approach resulted in 64 microRNAs that may
potentially bind to 3’UTR of TP63 and regulate ΔNp63 expression upon activation of
TGFβ signaling (Figure 35D). Among the 64 microRNAs, 9 microRNAs, including
miR-10b, miR-21, miR-22, miR-30a, miR-141, miR-181a, miR-200a, miR-203a and
miR-222, were selected for further validation based on predicted binding affinity to
3’UTR of TP63 and previously reported connection with breast cancer or ΔNp63.
Overexpressing mimics of these 9 microRNAs demonstrated that miR-22, miR-30a,
miR-203a and miR-222 were able to down-regulate ΔNp63 protein level in DCIS
cells (Figure 36A). Similar results were obtained in 10A and CA1D cells (Figure
36B). Moreover, these 4 microRNAs showed direct interaction with the 3’UTR of
TP63 gene in luciferase assay (Figure 36C-J), confirming regulatory effects of these
4 microRNAs on ΔNp63 expression in breast cancer cells.
Notably, TGFβ signaling was confirmed to up-regulate expression of these 4
microRNAs (Figure 37A-D). Chromatin immunoprecipitation data revealed direct
binding of Smad2/3 to the promoter regions of these 4 microRNAs, proposing the
regulation of ΔNp63 via TGFβ/microRNAs axis (Figure 37E-H). Interestingly,
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inhibition of both miR-30a and miR-203a or all 4 microRNAs, but not single
microRNA, rescued the expression of ΔNp63 in the presence of TGFβ (Figure 37IK). This suggests synergistic effects of the microRNAs in regulating ΔNp63
downstream of TGFβ signaling in breast cancer.
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Figure 35:

Identification of TGFβ-induced microRNAs that potentially

regulate ΔNp63 expression. A-B, qRT-PCR (A) and western blot (B) to detect
ΔNp63 mRNA level upon TGFβ and LY2157299 treatment. Actin was used as
loading control. C, Heatmap of differential expressed microRNAs between TGFβtreated and –non-treated DCIS cells. D, Venn diagram showing 64 TGFβinduced microRNAs that are predicted to bind to 3’UTR of p63.
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Figure 36: miR-22-3p, miR-30a-5p, miR-203a-3p and miR-222-3p regulate
ΔNp63 expression in breast cancer cells. A, Western blot for ΔNp63 expression
in DCIS cells transfected with indicated microRNA mimics. B, Western blot for
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ΔNp63 expression in 10A, DCIS and CA1D cells transfected with miR-22-3p, miR30a-5p, miR-203a-3p or miR-222-3p mimics. Actin was used as loading control. C-J,
Luciferase signal of DCIS cells transfected with 3’UTR of TP63 wild type or mutated
at binding sites to miR-22-3p (C-D), miR-30a-5p (E-F), miR-203a-3 (G-H), miR-2223p (I-J) and indicated microRNA mimics. Asterisk indicate statistical significance,
p <0.05 versus p63-WT + control mimics. two-tailed t test.
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Figure 37: TGFβ represses ΔNp63 expression via miR-22-3p, miR-30a-5p, miR203a-3p and miR-222-3p. A-D, Taqman qRT-PCR for expression of miR-22-3p (A),
miR-30a-5p

(B),

miR-203a-3p

(C)

and

miR-222-3p

(D)

upon

TGFβ

or

TGFβ+LY2157299 treatment. Asterisk indicate statistical significance, p <0.05
versus DMSO. two-tailed t test. E-F, Chromatin immunoprecipitation to detect
binding of Smad2/3 to the promoter of miR-22-3p (E), miR-30a-5p (F), miR-203a-3p
(G) and miR-222-3p (H) upon TGFβ treatment. Asterisk indicate statistical
significance, p <0.05 versus control without TGFβ. two-tailed t test. I-J, Western blot
for ΔNp63 expression in DCIS cells treated with indicated microRNA inhibitors.
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6. CHAPTER 6: CONCLUSIONS, DISCUSSION AND FUTURE DIRECTIONS
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Chapter 6: Conclusions, Discussion and Future directions

6.1 Conclusions and Discussion
Adding to current knowledge of the p53/p63/p73 field, my thesis work further
explored an intricate network of functions of ∆Np63 isoform in physiological and
pathological processes, especially in cancer progression and metastasis. Firstly, I
demonstrated that the loss of ∆Np63 in basal epidermal cells triggers an EMT
program with decreased expression of E-cadherin and increased expression of
Vimentin, Twist1, Lef1, Snail1 and Zeb1. ∆Np63-deficient keratinocytes exhibit
increased migration and invasion capacity in vitro. In addition, ∆Np63 depletion in
basal keratinocytes during wound healing induces an “irreversible” EMT via
activation of transcription factors Twist1 and Lef1, delaying the wound healing
process in vivo. I further showed that Twist1 and Lef1 are modulated during the
induction of EMT upon ∆Np63 depletion via miR-98-3p and miR-34a-5p,
respectively. These microRNAs are positively regulated by ∆Np63, possibly through
DGCR8.

Together,

my

findings

identify

the

involvement

of

a

∆Np63/microRNAs/Twist1, Lef1 axis in the regulation of EMT in basal epidermal
cells and wound healing (Manuscript in preparation).
Secondly, my work revealed pleiotropic roles of ΔNp63 in tumor development
and progression (135). Specifically, while TAp63 exhibits a consistent tumor
suppressive role during tumor development and progression among various
cancers, ΔNp63 plays a pleiotropic role as either a tumor suppressor or an
oncogene during tumor development in different cancers. In breast cancer (BRCA)
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and lung squamous cell carcinoma (LUSC), ΔNp63 activates an oncogenic program
through transcriptional regulation of its downstream target, Lef1. ΔNp63, on the
other hand, functions as a tumor suppressor in kidney clear cell carcinoma (KIRC)
during tumor development. Although Lef1 is also regulated by ΔNp63 in KIRC
cancer, it fails to exert ΔNp63 tumor suppressive functions in this type of cancer.
Other factors rather than Lef1 may be responsible for ΔNp63 tumor suppressor roles
in KIRC cancer. Interestingly, the loss of ΔNp63-regulated transcriptional activities,
together with enrichment of stem cell, ECM remodeling and EMT signatures are
observed in higher stages of BLCA, KIRC, KIRP and LGG, suggesting a tumor
suppressive role of ΔNp63 during cancer progression.
Thirdly, I further demonstrated that a dynamic regulation of ΔNp63 enhances
metastatic dissemination in breast cancer. ΔNp63 is essential for primary tumor
growth, confirming oncogenic roles of ΔNp63 during breast cancer development.
This observation is in line with previously published studies in other types of cancer
in our lab (25, 27). ΔNp63 is also required for lung extravasation and subsequent
colonization to form overt metastatic colonies. Strikingly, continuous depletion of
ΔNp63 in tumor cells increases metastatic frequency to the lungs compared to
control mice. More importantly, a modulation of ΔNp63 level during metastatic
cascade results in highest frequency of metastatic colonization to the lungs,
indicating that a dynamic regulation of ΔNp63 during breast cancer metastasis
enhances metastatic dissemination. Additional work revealed a TGFβ/microRNAs
axis in modulating ΔNp63 expression in breast cancer. The activation of canonical
Smad-dependent TGFβ signaling down-regulates expression of ΔNp63 via a
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network of TGFβ-induced microRNAs, including miR-22-3p, miR-30a-5p, miR-203a3p and miR-222-3p. These microRNAs cooperatively function to regulate expression
of ΔNp63 in breast cancer (Manuscript in preparation).

6.1.1 Depletion of ΔNp63 elicits an EMT program in epidermal cells
∆Np63 is the predominant isoform expressed in the epidermal basal
keratinocytes and pivotal for the maintenance of stem-like characteristics and the
terminal differentiation of these cells (16, 33-35). Two studies generated isoform
specific- knockout mouse models for ∆Np63 and emphasized its role as a master
regulator of epidermal development. Here, I showed that keratinocytes isolated from
∆Np63-/- mice undergo dramatic change in morphology from epithelial-like to
mesenchymal-like with the acquisition of mesenchymal characteristics, revealing
activation of an EMT program in these cells. Moreover, increased invasiveness was
also noted in these ∆Np63-deficient keratinocytes. These findings are in line with
several reports on the induction of EMT upon the depletion of p63 in several cell
types, including squamous cells, mammary epithelial cells, metastatic prostate
cancer, cervical cancer and bladder cancer cells (30, 95-97, 154). However, majority
of these studies used a total p63 knockdown or ∆Np63α/β/γ isoforms overexpression
approach, which did not take into account the existence of the TAp63 isoforms and
the complex regulatory network among p63 members.
By utilizing a ∆Np63-specific knockout mouse model, our data demonstrate
isoform-specific function of ∆Np63 in modulating EMT in epidermal cells. Especially,
the depletion of ∆Np63 in keratinocytes results in a complete activation of EMT
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program with the upregulation of multiple EMT-drivers, including Twist1, Snail1,
Zeb1 and Lef1 (Figure 8). Zeb1 has been shown to be upregulated upon the
knockdown of ∆Np63 via direct transcriptional activation of miR-205 in several
cancer cells (30, 31, 96). Another study also reported decreased expression of
Twist1, Snail1 and Zeb1 when ∆Np63α was overexpressed in spindle cell
carcinomas cell lines derived from Trp53ΔEpi;Rb1ΔEp spontaneous skin tumors (155).
My findings, together with previously published data, consolidate the inhibitory
effects of ∆Np63 on EMT in various transformed and non-transformed cell lines.
Given the high expression of ∆Np63 found in majority of epithelial tissues and
its loss of expression in mesenchymal cells, the regulatory functions of ∆Np63 in
EMT may serve as a molecular switch between epithelial and mesenchymal state.
Therefore, down-regulation of ∆Np63 in epithelial cells leads to activation of an EMT
program, favoring mesenchymal characteristics. Conversely, up-regulation of ∆Np63
in mesenchymal cells induces an MET program and reverses the cells into epithelial
state. The fact that keratinocytes in the proliferative basal layer lose expression of
∆Np63 during terminal differentiation into suprabasal cells further establishes ∆Np63
as a crucial modulator of cell fate (16, 34, 156). This molecular switch function is
particularly important during cancer metastasis where tumor cells have to transition
through a broad spectrum of EMT to shuttle between epithelial and mesenchymal
state (47). Recently, with more insights into characteristics of metastasizing tumor
cells, the concept of a reversible “partial” EMT has been increasingly favored in
explaining the highly plastic nature of tumor cells in order to colonize and spread
new tumors to distant organs (47, 79, 99). As the center of this EMT regulatory
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network with the ability to orchestrate multiple EMT-drivers and control cell fate,
∆Np63 upholds its pivotal roles in many physiological and pathological processes.

6.1.2 Loss of ∆Np63 in epidermal cells delays wound healing process in vivo
During wound repair process, keratinocytes at the migratory edges of the
wound undergo a “partial” EMT in order to increase motility and move toward
wounded sites. Thanks to the plastic nature of this “partial” EMT, the migrating
keratinocytes can reverse to epithelial state to cover the wound with new layers of
epithelial cells (43, 47, 74). Since the depletion of ∆Np63 induces a complete EMT in
which keratinocytes acquire various properties of mesenchymal cells, I hypothesized
that the complete EMT would prevent or delay wound healing process due to the
incapability to reverse to epithelial state of ∆Np63-depleted keratinocytes. There are
studies aiming to develop in vivo models to fully understand mechanisms of action of
∆Np63 in skin development and homeostasis (157, 158). However, the fact that
∆Np63-/- mice die shortly after birth with severe defects in skin structure has posed
great challenges for these studies (5, 7). Koster et al. developed an inducible
∆Np63-knockdown mouse model to specifically knock down ∆Np63 in epidermal
cells using si∆Np63 induced upon topical treatment with RU468 (158). With an
opposite approach, Romano et al. generated a tetracycline-inducible ∆Np63αoverexpressing mouse model to investigate contribution of ∆Np63 in hair follicle
development (157). Nevertheless, these models still exhibited certain limitations.
With Koster’s model, the knockdown efficiency by siRNA did not guarantee a
complete depletion of ∆Np63 in epidermal cells in vivo. Off-target effects might
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complicate the phenotype. The lack of a tracing marker also hindered attempts to
follow ∆Np63-depleted cells in vivo. The overexpression approach from Romano’s
model, on the other hand, did not take into account the existence of ∆Np63β and γ in
addition to the α isoform and potential crosstalk among the isoforms.
To overcome these issues, we utilized the ∆Np63-conditional knockout
(∆Np63fl/fl) mouse model generated in the Flores lab (7) to develop an in vivo
cutaneous wound healing model to examine functions of ∆Np63 during normal
wound repair. By crossing ∆Np63fl/fl mice to RosaM/M mice and K14CreER+ mice to
generate ΔNp63fl/fl, RosaM/M, K14CreER+ triple mutant mice, we can specifically ablate
∆Np63 in epidermal basal cells expressing K14. The addition of the RosaM/M alleles
provided a fluorescence tracing marker of RFP/GFP to follow the recombination in
vivo. The results showed that depletion of ∆Np63 in epidermal cells delays wound

healing process in vivo. While ethanol-treated mice (ΔNp63fl/fl) displayed a full re-

epithelialization over wounded sites 4 days post-wounding, tamoxifen-treated mice
(ΔNp63∆/∆) still had open wounds even 8 days after wounding (Figure 10C-E). Koster
et al. reported a similar phenotype observed in their ∆Np63-knockdown mouse
model 96 hours post-wounding (158), further suggesting an important role of ∆Np63
in normal wound repair. Notably, these ∆Np63-deficient epidermal cells did not
exhibit defects in cell proliferation (Figure 11). This observation is in accordance with
previously published data from our lab in which ∆Np63-deficient epidermal cells
showed high BrdU staining (7, 158), whereas Romano et al. documented an
opposite phenotype in which ∆Np63-deficient epidermal cells exhibited reduced
proliferative capacity in their ∆Np63-knockout model (5). These discordant findings
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might arise different approaches used to make the ∆Np63-knockout model in which
Chakravarti et al. deleted the 3’ exon of ∆Np63 transcript (7), while Romano et al.
replaced the 3’ exon with GFP (5). Since ∆Np63-depleted epidermal cells still
maintained high proliferative capacity 8 days after wounding, but failed to reepithelialize wounded sites, I asked whether a complete induction of EMT in these
cells upon ∆Np63 loss delayed the healing process. In fact, ∆Np63-depleted
epidermal cells (GFP positive) at wounded sites displayed decreased E-cadherin
and increased Vimentin expression (Figure 12), indicating occurrence of EMT in
these cells. Thus, a complete EMT instead of a “partial” EMT upon ∆Np63 depletion
prevents migrating keratinocytes to reverse to epithelial state in order to fully reepithelialize the wounds. However, there is no evidence whether the loss of ∆Np63
would slow down or completely block wound healing. I attempted to extend the
experimental time points longer than 8 days to determine whether the wounds would
eventually heal. Unfortunately, the mice died after 10 days post-wounding. Possibly,
there are potentials that wounded sites would eventually heal since dermal stem cell
compartments in the hair follicles also contribute to replenish damaged cells during
wounding (73). Taken together, our data support a model in which impaired function
of ∆Np63 delays wound healing process in vivo through regulation of EMT program.

6.1.3 ∆Np63 modulates EMT via regulating transcription factors, Twist1 and
Lef1
I have demonstrated that ∆Np63 regulates EMT in epidermal cells via
modulating several EMT-associated transcription factors, including Twist1, Snail1,
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Zeb1 and Lef1. Notably, induction of Twist1 and Lef1 expression was also observed
in ∆Np63-depleted epidermal cells at wounded sites during wound healing process
(Figure 13), suggesting the involvement of these transcription factors in ∆Np63regulated EMT during wound repair. In order to further explore mechanisms of action
of ∆Np63 in modulating these factors, I first examined whether there is a direct
transcriptional regulation of ∆Np63 to these genes. Nevertheless, no direct binding
at the promoters of Twist1 and Lef1 was observed (Figure 12F-G), suggesting an
indirect regulation of ∆Np63 on the expression of these genes.
microRNAs have been intensively shown to involve in regulatory networks of
EMT-associated transcription factors (41, 60). Furthermore, ∆Np63 has been
reported to globally modulate microRNA biogenesis via direct transcriptional
activation of DGCR8 (7), proposing a possible regulation of Twist1 and Lef1 by
∆Np63 via microRNAs. By performing a RNA-microRNA pair analysis on our
available RNA-sequencing and microRNA-sequencing data on wild type and
∆Np63-/- keratinocytes (7), I found a network of ∆Np63-induced microRNAs that
potentially regulate Twist1, Lef1 and Zeb1 in epidermal cells, including miR-98-3p
and miR-34a-5p (Figure 15A). Further work showed that ∆Np63 indeed inhibits
expression of Twist1 and Lef1 through miR-98-3p and miR-34a-5p in keratinocytes,
respectively (Figure 16A-D). Subsequently, overexpression of miR-98-3p and miR34a-5p in ∆Np63-/- keratinocytes reduced migration and invasion capacity (Figure
16E-F), further confirming a ∆Np63/microRNAs/Twist1 and Lef1 axis in modulating
EMT and cell migration, invasion.
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Although the induction of a partial EMT during wound healing with cells at the
migratory front expressing Vimentin and Fsp1 has been reported (159), the
expression of Twist1 and Lef1 during wound repair is distinctive for ∆Np63-deficient
keratinocytes since I did not observe increased expression of either Twist1 or Lef1 at
day 1 after wounding in ethanol-treated group (Figure 13). Twist1 is one of the
master drivers of EMT and has been implicated as an oncogene in multiple cancers
(160). However, few microRNAs have been identified to regulate Twist1 expression
during EMT, including let-7d, miR-29b and miR-214 (67-69). Those microRNAs did
not come up in our RNA-microRNA functional pair analysis. Instead, miR-98-3p was
connected to Twist1 in our analysis. TargetScan predicted Twist1 as a potential
downstream target of miR-98-3p. My data also confirmed that the overexpression of
miR-98-3p in ∆Np63-/- keratinocytes reduced expression of Twist1, suggesting
regulatory activity of miR-98-3p to Twist1. Interestingly, miR-98 precursor is a
member of let-7 family, and let-7d has been shown to repress EMT via downregulating Twist1 (69). In addition, a recent study revealed that let-7b
overexpression inhibits re-epithelialization and delays wound healing through
repression of IGF2BP2, then preventing migration in keratinocytes (161). These
findings further support our data on important regulatory function of a ∆Np63/miR98/Twist1 axis in normal wound repair. Likewise, Lef1 is a transcription factor
involved in the Wnt/β-catenin signaling pathway and also a known modulator of
EMT. During EMT program, Lef1 represses expression of E-cadherin independent of
β-catenin recruitment (162). miR-34a has been demonstrated to regulate expression
of Lef1 in several cancers (163). In this study, I identified miR-34a as a downstream
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target of ∆Np63, exerting its regulation on EMT during wound healing via repressing
Lef1 in epidermal cells.
In summary, this part of my work identified ∆Np63 as a master regulator of
EMT in epidermal cells via modulating expression of major EMT-drivers, including
Twist1 and Lef1. A complete activation of an EMT program in epidermal cells upon
∆Np63 depletion leads to a delay in wound repair, further supporting the pivotal roles
of ∆Np63 in normal skin development and homeostasis. The identification of two
novel ∆Np63/microRNA axes in regulating EMT in epidermal cells is particularly
significant given the fact that microRNAs play crucial roles in wound healing process
and have been proposed as promising therapeutic targets to treat chronic wounds
(164). Hence, both miR-98-3p and miR-34a-5p

are potential novel targets for

treatment of chronic wounds.

6.1.4 Pleiotropic roles of ΔNp63 in tumor development and progression
Although numerous studies have explored isoform-specific functions of p63 in
cancers, a conclusive answer is still missing due to the existence of multiple
isoforms with opposing functions and an intricate regulatory network among the
isoforms (4, 18, 35). With a novel approach to perform a pan-cancer analysis using
TCGA and unique transcriptome profiles generated from TAp63-/- and ΔNp63-/epidermal cells, we found a consistent tumor suppressive pattern of TAp63 across
multiple cancers in both tumor development and progression, whereas ∆Np63
exhibits pleiotropic roles as either an oncogene or a tumor suppressor in different
types and stages of cancers. Particularly, ∆Np63 demonstrates tumor-promoting
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activity during the development of 7 cancers, including some of the most prevalent
cancers

such

as

breast

cancer

(BRCA),

bladder

cancer

(BLCA),

lung

adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) (Figure 17B).
The oncogenic functions of ∆Np63 have been elucidated in thymic lymphomas via
∆Np63/TAp63/IAPP axis and in cutaneous squamous cell carcinomas (cSCC) via
∆Np63/DGCR8/microRNAs axis (25, 27). Unpublished data from the Flores lab have
also unveiled tumor-promoting roles of ∆Np63 in LUAD and LUSC. Little has been
known regarding mechanisms of action of ∆Np63 in the development BRCA and
BLCA. A recent study revealed that ∆Np63 promotes tumor initiating cells in basallike mouse mammary tumors via direct transcriptional regulation of Fzd7, a
component of the Wnt signaling pathway (143), further supporting our TCGA data on
an oncogenic role of ∆Np63 in breast cancer development. More interestingly, our
TCGA pan-cancer analysis also identified ∆Np63 as a tumor suppressor in the
development of kidney clear cell (KIRC), heck and neck squamous cell carcinoma
(HNSCC) and stomach adenocarcinoma (STAD). This finding in HNSCC is
conflicting with published studies on p63 activities in HNSCC where ∆Np63 is often
found to be overexpressed and exerts its tumor-promoting functions via suppression
of p73-induced apoptosis (125, 126, 165, 166), suggesting a perplexing involvement
of ∆Np63 in HNSCC and the necessity of further work to provide a complete insight
into how ∆Np63 functions in HNSCC.
In contrast with its oncogenic roles in cancer development, ∆Np63 shows a
prevalent tumor suppressor role in 5 out of 6 cancers during tumor progression,
including kidney renal clear cell (KIRC), kidney papillary (KIRP), kidney
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chromophobe (KICH), bladder cancer (BLCA), and low grade glioma (LGG).
Strikingly, BLCA is the only cancer in which ∆Np63 exerts its oncogenic functions
during tumor development, but tumor suppressive roles during tumor progression.
Even though the contribution of ∆Np63 in the development of BLCA remains elusive,
the loss of p63 has been documented in invasive bladder cancer and is associated
with tumor progression (167). Importantly, ΔNp63 depletion in epithelial-like bladder
cancer cells promotes EMT, increasing cell migration and invasion, while the
overexpression of ΔNp63 in mesenchymal-like bladder cancer cells elicits MET and
suppresses invasion (31). These data support a model in which ΔNp63 exhibits a
two-faceted role during cancer development and progression.
We further employed these distinct signatures to predict patient survival in
BLCA, KIRC, KIRP and LGG. High grade/stage tumors of BLCA, KIRC, KIRP and
LGG showed the loss of ΔNp63 activities when tumors progressed to more
advanced stages. Particularly, KIRC and LGG patients with high ΔNp63 activity had
significantly better survival than patients with lower activity (Figure 24), proposing
ΔNp63-driven signature as a potential prognosis tool for p63-isoform specific
therapeutic interventions. The enrichment of pluripotency, EMT and ECM
remodeling-related pathways in the ΔNp63-driven signature may be accountable for
the association between the loss of ΔNp63 activities and tumor progression since
these pathways have been implicated in cancer progression and metastasis (Figure
25).
Of note, our approach of utilizing TAp63- and ΔNp63-driven signatures
derived from mouse epidermal keratinocytes and comparing them to expression
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profiles across various cancer types might rise concerns regarding cross-species
comparison and differential basal expression of TAp63/ΔNp63 in different tissue
types. Nonetheless, our approach aimed to investigate specific functions of
TAp63/ΔNp63 in each type of cancer based on significance, directionality and
enrichment concordance between their transcriptional activities and development or
progression signatures from each tumor type regardless of their basal expression
level in those tumors. In fact, our data showed a correlation between ΔNp63 basal
expression and its transcriptional activities as either an oncogene or tumor
suppressor indicated in our analyses (Figure 19A). Additionally, in this study, we
chose ΔNp63-driven signatures derived from ΔNp63-/- keratinocytes where ΔNp63 is
highly expressed and has been shown to play pivotal roles in modulating
differentiation and homeostasis of these cells as starting materials. We do not rule
out the possibility that different starting materials can result in different ΔNp63-driven
signatures. Yet, by using this ΔNp63-/- signature, we aimed to obtain the most
complete network of its downstream targets possible that can be utilized as a
platform for comparison of its transcriptional activities in various tissue types. The
fact that some cancers, such as BRCA and BLCA, can be sub-divided into distinct
molecular subtypes with different expression level of p63 may complicate the
outcome of our study in which we did not specifically investigate functions of ΔNp63
in different subtypes of BRCA and BLCA. However, as aforementioned, since our
method is based on comparison of ΔNp63-driven transcriptional signature, not
ΔNp63 basal level, we believe that our work still provides potential prediction tools to
further stratifying patients into groups that can benefit from p63-isoform specific
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targeted therapy. This is particularly important in the context of p63-related pathways
have increasingly been implicated in re-classifying cancers into distinct molecular
subtypes (125, 126).

6.1.5 ΔNp63

activates

an

oncogenic

program

through

transcriptional

regulation of its downstream target, Lef1
To further understand the molecular switch that dictates oncogenic or tumor
suppressive activities of ΔNp63 in cancer, we identified Lef1 as a downstream target
of ΔNp63 in BRCA, LUSC and KIRC (Figure 21 and Figure 23). In BRCA and LUSC
cell lines, ΔNp63 exerts its tumor-promoting activity through transcriptional activation
of Lef1. Knockdown of Lef1 in these cells mimicked the effects of ΔNp63 depletion
on reducing anchorage-independent growth of cancer cells. Overexpression of Lef1
in ΔNp63-depleted cells rescued the phenotype (Figure 22), further confirming the
activation of a ΔNp63-dependent oncogenic program via Lef1 in BRCA and LUSC.
In HCC95 LUSC cell line, ΔNp63/Lef1 axis demonstrated significant tumorpromoting effects only in anchorage-independent growth but not cell proliferation,
suggesting the uncoupling of ΔNp63-induced tumor initiating capacity and cell
growth in LUSC. In Caki-1 KIRC cell line with undetectable expression of ΔNp63,
ΔNp63 exhibits tumor-suppressive role in decreasing anchorage-independent
growth (Figure 20I-L). Although Lef1 is still a downstream target of ΔNp63 in Caki-1
cells, it fails to exert ΔNp63 tumor-suppressive functions in these cells, indicating the
involvement of other alternative pathways.
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As mentioned before, Lef1 is a component of Wnt signaling pathway and has
been implicated in multiple cancers (162). Particularly, Lef1 has involved in
promoting breast cancer progression and metastasis through various mechanisms
(168-170), which is in line with our finding of the oncogenic ΔNp63/Lef1 axis in
BRCA. On the other hand, functions of Lef1 in LUSC and KIRC remain large
unknown. Notably, I found that ΔNp63 positively regulates Lef1 in these cancer cells,
whereas ΔNp63 represses expression of Lef1 via miR-34a-5p in basal epidermal
cells. These discrete observations in normal and cancer cells on the regulatory
effects of ΔNp63 on Lef1 prompted a question on cell type-specific transcriptional
activity of ΔNp63. When ΔNp63 was knocked down in normal mammary epithelial
cells MCF10A, I also observed an increased in Lef1 expression, while depletion of
ΔNp63 in MCF10DCIS breast cancer cells decreased level of Lef1 (data not shown),
further suggesting distinct transcriptional regulatory activities of ΔNp63 on certain
subsets of its downstream targets. Especially, ΔNp63 shows no direct transcriptional
regulation to the promoter of Lef1 in epidermal cells, but regulates its expression via
microRNA network, indicating other microRNAs rather than miR-34a may be
involved in ΔNp63-induced expression of Lef1 in BRCA, LUSC and KIRC cells.
Taken together, this study constitutes the largest analysis of ΔNp63
transcriptional network across multiple cancers from TCGA platform. With this pancancer analysis, we revealed a ΔNp63-driven signature from ΔNp63-/- keratinocytes
that can predict cancer development, progression, and patient survival. Our findings
elucidate a dual role of ΔNp63 as either a tumor suppressor or an oncogene in the
development of cancer, and its regulation of Lef1 is essential for its oncogenic
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functions in BRCA and LUSC. Likewise, ∆Np63 consistently acts as a suppressor of
cancer progression, which is in accordance with published data in multiple cancers.
Moreover, the ∆Np63-driven signatures identified in our integrative bioinformatics
analyses can stratify clusters of patients with differential expression profiles for
pluripotency, ECM and EMT-associated markers that can be beneficial for p63isoform specific treatment.

6.1.6 Dynamic regulation of ∆Np63 in breast cancer progression and
metastasis
Given its crucial roles in epithelial cells and high expression in mammary
glands, there have been several studies investigating the roles of ∆Np63 in the
progression and metastasis of breast cancers (29, 32, 120, 143). However, the
answer on whether ∆Np63 is an oncogene or tumor suppressor in breast cancer
remains elusive due to conflicting data reported. Chakrabarti et al. and Franco et al.
agreed on a tumor-promoting role of ∆Np63 in breast cancer formation (120, 143).
Franco et al. and Giacobbe et al. also provided evidence for ∆Np63 as a promoter of
breast cancer metastasis through different pathways (32, 120). Conversely,
Bergholz et al. showed that ΔNp63 inhibits cell invasion and metastasis in breast
cancer by negatively regulating Erk signaling via direct transcriptional activation of
MKP3 (29). These discordant observations may arise from the fact that these
studies utilized different systems most of which are in vitro assays. They also failed
to examine the contributions of ΔNp63 from tumor formation to subsequent
metastatic colonization as a complete process instead of only looking into snapshot
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events during that process. Particularly, while our pan-cancer analysis from TCGA
platform also pointed out oncogenic role of ΔNp63 during tumor development, we
did not obtain significant data for tumor progression (135). Therefore, it is essential
to develop an in vivo system that allows us to investigate mechanisms of action of
ΔNp63 from primary tumor establishment to metastatic colonization to distant
organs, especially when there are evidences for the pleiotropic roles of ΔNp63 in
tumor development and progression from various studies. Interestingly, my data on
the clinical association of ΔNp63 and breast cancer progression revealed the loss of
ΔNp63 in high stage breast cancer samples, together with the correlation with poor
survival (Figure 27). Further, I also observed an increase in the number of primary
tumors having low expression of ΔNp63 while their corresponding metastases still
retained high level of ΔNp63 in higher stage samples (Figure 28). These data further
suggest a two-faceted role of ΔNp63 in the development of primary tumors and
establishment of distant metastases.
In fact, by utilizing an in vivo inducible knockdown system for ΔNp63, I found
that ΔNp63 is essential for not only formation and growth of breast primary tumors
but extravasation and lung colonization as well (Figure 31Figure 32). These findings
are in line with previous reports on the oncogenic roles of ΔNp63 in promoting tumor
growths in multiple cancers, including breast cancer (25, 27, 120, 135, 143).
Strikingly, the knockdown of ΔNp63 in established tumors led to increased
metastatic frequency to the lung, indicating a suppressive role of ΔNp63 in
intravasation of invading tumor cells. Further, a dynamic regulation of ΔNp63 in
which ΔNp63 was down-regulated in established tumors for a period of 3 weeks,
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then brought back up for 3 more weeks showed highest metastatic colonization to
the lungs (Figure 33). More importantly, all metastatic colonies in the lungs exhibited
high expression of ΔNp63 regardless of treatment groups, suggesting the
indispensable role of ΔNp63 for circulating tumor cells to establish new tumors at
distant sites. The high expression of ΔNp63 in metastases arose from ΔNp63depleted cells indicates two possibilities. First, the ΔNp63-depleted circulating cells
may gain expression of ΔNp63 via other alternative pathways that bypass the effects
of the shΔNp63. Second, since the system is an inducible knockdown using shRNA,
there is chance of inefficient knockdown in a subset of tumor cells. However,
regardless of the underlying reasons, the high expression of ΔNp63 in all
metastases further confirms essential roles of ΔNp63 in metastatic establishment.
This is in accordance with the facts that ΔNp63 expression is crucial for the
maintenance of epithelial characteristics and that the reversion to epithelial state of
circulating tumor cells arrested at distant organs is important for metastatic
colonization (79, 99). These intriguing findings support a two-faceted role of ΔNp63
in breast cancer progression and metastasis in which ΔNp63 is required for tumor
cell growth at both primary sites and distant organs, whereas losing its expression in
a certain subset of invading cells in the primary tumors elicits intravasation into the
circulation. Subsequent re-expression of ΔNp63 in circulating cells facilitates
colonization to the lungs. The loss of ΔNp63 in primary tumor cells may elicit an
EMT program to increase cell migration and invasion, subsequently promoting
intravasation. This model can explain the opposing results from studies trying to
understand functions of ΔNp63 in the development and metastasis of breast cancer.
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In Bergholz’s study, the authors knocked down total p63 in transformed mammary
epithelial cells and saw increased in metastatic incidence to the lungs when injecting
the cells via tail vein (29). However, by using a shRNA for total p63, this approach
did not take into account the existence of TAp63 isoforms and dominant negative
effects of ΔNp63 over TAp63 that might complicate the phenotype. Previously,
Cheung et al. proposed a model for collective invasion in which leader cells at the
invading front often express K14 and p63, suggesting important contributions of p63
in initiating collective invasion of breast cancer (122). Nonetheless, we do not find
these observations conflicting with our proposed model in which the loss of ΔNp63
may facilitate invasion and intravasation of single tumor cells. In fact, given the
intricate interplay between the two modes of collective and single cell invasion in
metastatic dissemination, our study and others suggest that ΔNp63 may function as
a molecular switch between the two modes of invasion. Perhaps, ΔNp63 and K14
high expression elicits a transition in tumor cells from luminal to basal state and
triggers collective invasion in luminal breast cancer, whereas a reduction in ΔNp63
level in ΔNp63-expressing tumor cells can initiate an EMT program and promote
invasion. Our subsequent findings on the regulatory network between TGFβ and
ΔNp63 further emphasize possible involvement of ΔNp63 as a molecular switch
between collective and single cell invasion.

Although Cheung et al. provided

evidence for a collective invasion program led by K14-expressing cells in HER2+
and basal breast cancer model, the authors failed to correlate K14 with p63
expression in the leader cells in these models and to examine whether p63 directly
involves in regulating K14 expression in these cells (122). A follow-up study from the
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same group demonstrating that polyclonal metastases arise from K14-expressing
cell clusters also did not investigate the relevance of p63 in this context (103). Given
heterogeneous expression status of p63/ΔNp63 in different breast cancer cell
lineages, it is important to consider their basal level prior to manipulation their
expression. Several highly metastatic basal breast cancer cell lines, such as MDAMB-231 and MDA-MB-468, do not express detectable level of ΔNp63 (data not
shown), suggesting that these cells may harbor genetic alterations that support them
to bypass the regulation of ΔNp63 during metastatic dissemination.
Therefore, attempts to classify cancers into different molecular subtypes
using integrated cross-platform analyses provided additional information for future
research on the contribution of ΔNp63, and p63 in general, in cancer development
and progression (125, 126). Moreover, given the intricate role of ΔNp63 in different
stage of breast cancer, it is essential to consider its specific function at each step of
tumor progression and metastasis. The utilization of different models, including in
vitro, ex vivo 3D organoid cultures and in vivo, will be also beneficial in obtaining a
comprehensive insight into perplexing functions of ΔNp63 in cancers. This is
particularly critical for the application of p63 isoform-specific therapeutic treatments
in which inhibiting ΔNp63 will result in the regression of tumors, yet pose a possibility
of increasing metastasis, especially when dormant disseminating cells have been
increasingly considered as a primary cause for tumor recurrence in cancer patients
(114).

145

6.1.7 TGFβ-induced microRNAs regulate ΔNp63 expression in breast cancer
Since ΔNp63 exhibits a complex two-faceted role in breast cancer
progression and metastasis, it is critical to determine underlying regulatory
mechanisms that dictate ΔNp63 expression and functions. The connection between
TGFβ signaling and ΔNp63 identified in my study reveals a novel regulatory network
for ΔNp63 in breast cancer. Through my work, TGFβ signaling represses expression
of ΔNp63 at post-transcriptional level in both normal mammary epithelial cells and
breast cancer cells via canonical Smad-dependent pathway (Figure 34). Differential
expressed microRNAs upon TGFβ treatment included several known targets of
TGFβ signaling such as miR-181, miR-145 and miR-21 (153), further confirming the
activation of TGFβ signaling in these cells. Intriguingly, 4 TGFβ-induced microRNAs
were identified as upstream regulators of ΔNp63, including miR-22-3p, miR-30a-5p,
miR-203a-3p and miR-222-3p. These microRNAs directly bind to 3’UTR of TP63 and
regulate expression of ΔNp63 (Figure 36). Especially, the inhibition of 4 microRNAs
or combination of miR-30a-5p and miR-203a-3p, but not any single microRNA,
rescued inhibitory effects of TGFβ on ΔNp63 expression, suggesting synergistic
effects of those microRNAs in regulating ΔNp63 downstream of TGFβ signaling
(Figure 38).
Given the complex nature of TGFβ signaling in metastatic cancer and that it is
often difficult to monitor TGFβ activity in vivo, numerous studies have unveiled
various downstream pathways of TGFβ signaling and its intricate crosstalk between
tumor cells and surrounding microenvironment (171). Activated TGFβ signaling has
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Figure 38: TGFβ-induced microRNAs modulate ΔNp63 expression. TGFβ binds
to TGFβRI to activate phosphorylation and translocation to the nucleus of Smad2/3
complex. p-Smad2/3 in the nucleus binds to the promoters of miR-22, miR-30a, miR203a and miR-222 to upregulate their expression. These microRNAs are then
processed and exported to the cytoplasm. In the cytoplasm, these microRNAs bind
to 3’UTR of TP63 and down-regulate translation of ΔNp63 protein.
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been strongly associated with increased metastatic dissemination via induction of
EMT program in tumor cells (151, 152, 172, 173). EMT-related transcription factors,
such as Snail1/2 and Zeb1/2, are downstream targets of TGFβ signaling (173). Yet,
impaired TGFβ signaling cascade also resulted in enhanced metastasis (174, 175).
More interesting, TGFβ has been shown to function as a molecular switch between
collective and single cell invasion programs in breast cancer (107), further
emphasizing pleiotropic roles of TGFβ in metastatic dissemination. Previous study
from Adorno et al. demonstrated that overexpression of TAp63 and ΔNp63 in p53mutant triple negative breast cancer cell line MDA-MB-231 abrogated TGFβ-induced
migration in these cells. The authors then unveiled that mutant-p53/p-Smad2 formed
a ternary complex with p63 to antagonize its inhibitory effects on TGFβ-induced
metastasis (176). My recent data revealed ΔNp63 as a downstream target of Smaddependent TGFβ signaling. Further, I proposed a model in which a transient and
localized activation of TGFβ signaling at the primary tumors triggers EMT and
increases invasion and intravasation of tumor cells into the circulation, whereas the
loss of activated TGFβ at distant sites facilitates metastatic colonization via reexpression of ΔNp63 (Figure 39). This model, together with Giampieri’s work (107),
supports TGFβ/ΔNp63 axis as a binary switch for tumor cells to transition between
different states (epithelial versus mesenchymal) and modes of invasion (collective
versus single cell) in a highly dynamic fashion, which ultimately favors metastatic
dissemination. In my opinion, by employing a regulatory network of signaling
cascade such as TGFβ to modulate ΔNp63, a critical modulator of cell fate and
differentiation, tumor cells have ability to quickly response to changes in the
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surrounding microenvironment in order to adapt, survive and thrive. However, we
also do not overlook the fact that our model may not be able to explain metastasispromoting effects of TGFβ signaling often observed in breast cancer. This could be
due to other alternative downstream pathways that TGFβ exploits to drive
metastasis, such as initiation of an EMT program independent of ΔNp63 via direct
transcriptional activation of Snail and Zeb as mentioned before. Additionally,
mutation status of p53 and basal level of p63 in tumor cells also contribute to the
regulatory network of TGFβ and p63 in cancer metastasis (176). In the presence of
mutant p53, ΔNp63 has been shown to oppose TGFβ-induced metastasis. Our
findings on the inhibitory effects of TGFβ on ΔNp63 suggest a potential negative
feedback loop in which cancer cells may exploit to overcome antagonistic activities
of ΔNp63 in TGFβ-induced metastatic dissemination. In addition, whether TGFβinduced downregulation of ΔNp63 in the primary tumor cells is a cell autonomous
phenotype

or

a

result

of

signaling

cascades

received

from

the

local

microenvironment requires further investigation. This is particularly critical when
interactions among tumor cells and stromal fibroblasts have been shown to have
significant effects on the outcome of TGFβ signaling in certain biological contexts
(171).

149

Figure 39: Proposed working model for the regulatory axis of TGFβ/ΔNp63 in
breast cancer metastasis

Among the 4 microRNAs, miR-203a-3p is a known modulator of ΔNp63
during epidermal terminal differentiation in the skin (39). The identification of this
microRNA as a downstream target of TGFβ signaling and its inhibitory effect on
ΔNp63 expression in breast cancer indicates a consistent role as a modulator of
ΔNp63 across different cell types. In breast cancer, the roles of miR-203 are still
debatable. Studies have shown its function as either a suppressor or promoter of
breast cancers (177, 178), suggesting a perplexing role of this microRNA in breast
cancer. Similarly, tumor-promoting and tumor-suppressive roles of miR-22 have also
been documented (179-181). miR-30a, on the other hand, has been consistently
demonstrated as a suppressor of breast cancer cell growth and metastasis (182184). Conversely, miR-222 has been implicated as oncogenes in breast cancer
metastasis by promoting EMT in basal-like breast cancer (185, 186). These
contradictory findings indicate a more complex regulatory network involving these
microRNAs in breast cancer, which partly explains why the inhibition of single
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microRNA could not rescue expression of ΔNp63 upon TGFβ induction. Of note,
since these microRNAs bind to the 3’UTR of TP63, both isoforms of ΔNp63 and
TAp63 will be potentially targeted. Given the predominant expression of ΔNp63 and
the frequent loss of TAp63 in cancers, these microRNAs presumably have the most
effect on modulating ΔNp63 level. However, as ΔNp63 transcriptionally represses
TAp63 and promotes tumorigenesis (25), we do not rule out a possibility that by
using these microRNAs to target ΔNp63, we will possibly prevent the upregulation of
TAp63 upon ΔNp63 depletion, which may hinder ΔNp63 to exert its tumor-promoting
functions via TAp63/IAPP axis. Yet, ΔNp63 has been demonstrated to promote
tumor development via other alternative pathways, such as modulation of
DGCR8/microRNAs axis or transcriptional regulation of Fzd7 in Wnt signaling (27,
143). Hence, in my opinions, despite of potential effects on TAp63, our approach of
utilizing these microRNAs to target ΔNp63 is still able to elicit its downstream effects
on tumorigenesis. In fact, I further showed that overexpression of miR-203a reduced
breast tumor growth in vivo (data not shown), suggesting that targeting both ΔNp63
and TAp63 by microRNAs resulted in the same phenotype as directly targeting
ΔNp63. In addition, the mechanisms of action of ΔNp63 during metastatic
dissemination have also been shown through various pathways that do not involve
TAp63 (29, 32, 94-96, 120, 154). Thus, I reason that our approach still provides
useful tools to target ΔNp63. Apparently, further investigations into detailed
regulatory mechanisms of TGFβ/microRNAs/ΔNp63 axis are required for a
comprehensive understanding on how to modulate this axis in favor of developing
treatments for metastatic breast cancer.
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Together, this part of my work unveiled the importance of a dynamic
regulation of ΔNp63 in breast cancer progression and metastasis. Specifically, while
∆Np63 is required for primary tumor growth of breast cancer, the loss of ΔNp63 in
tumor cells at primary sites promote the dissemination of tumor cells into circulation.
In addition, ΔNp63 expression is essential for circulating tumor cells to colonize and
form macro-metastases at distant organs. Importantly, I identified a novel regulatory
network of TGFβ and microRNAs to modulate expression of ΔNp63 in breast cancer.
These microRNAs are potential targets for biomarkers and therapeutic intervention
through TGFβ/microRNAs/ΔNp63 axis to diagnose and treat metastatic breast
cancer.

6.2 Future directions
Throughout my work, I demonstrated an intricate network of functions of
ΔNp63 in regulating EMT, cancer progression and metastasis. These findings further
emphasize the importance of understanding isoform-specific functions of p63 in
particular biological contexts, and open up new directions in utilizing ΔNp63associated regulatory pathways to discover novel targeted therapies and diagnostic
biomarkers.
The identification of a ΔNp63/microRNAs/EMT-drivers axis in normal wound
repair suggests miR-98-3p and miR-34a-3p as potential therapeutic targets to treat
chronic wounds. In addition, our pan-cancer analysis on activities of ΔNp63 across
different types and stages of cancers provided not only a platform for further
research into mechanisms of action of ΔNp63 in specific cancers, but integrative
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bioinformatics analyses that help to stratify patients using ΔNp63-driven signatures
in order to predict patient survival and response to p63-isoform specific treatments.
Finally, with the findings of novel TGFβ/microRNAs/ΔNp63 axis in breast cancer
progression and metastasis, further research on clinical correlation of these
microRNAs and ΔNp63 in different subtypes and stages of breast cancer can unveil
potential diagnostic markers and therapeutic targets to diagnose and treat metastatic
breast cancer. In vivo mouse models to modulate this axis are also beneficial for
further exploration of mechanistic pathways that are important for breast cancer.
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Appendix 1: Differential expressed microRNAs in DCIS cells treated with TGFβ

miRNA

logFC

AveExpr

P.Value

adj.P.Val

[TGFb/DMSO]
hsa-miR-222-3p

1.852874051

10.28652968

1.08E-08

8.92E-06

hsa-miR-181a-5p

1.536936491

8.966459296

2.34E-08

9.70E-06

hsa-miR-190a-5p

1.317850548

5.474452591

2.68E-07

7.39E-05

hsa-miR-30d-5p

1.130461624

6.865746322

6.44E-07

0.000133

hsa-miR-21-5p

1.33722637

12.00925218

2.55E-06

0.000233

hsa-miR-22-3p

1.042746137

8.846312647

2.18E-06

0.000233

hsa-miR-29a-3p

0.969794022

11.02280024

2.70E-06

0.000233

hsa-miR-29b-3p

0.986454772

14.54630567

2.26E-06

0.000233

hsa-miR-30a-5p

1.366165794

7.69174656

1.83E-06

0.000233

hsa-miR-3195

1.180313606

5.89430167

2.82E-06

0.000233

hsa-miR-146a-5p

0.973195168

8.667250081

3.89E-06

0.000293

hsa-miR-31-5p

1.080290369

6.598788926

6.16E-06

0.000425

hsa-miR-181b-

1.053462197

6.741762331

7.37E-06

0.000469

hsa-miR-361-3p

1.054866608

5.616265888

1.09E-05

0.000642

hsa-miR-548d-5p

0.839881597

5.908125905

2.44E-05

0.001349

hsa-miR-203a-3p

0.950556529

5.729458349

2.96E-05

0.00153

hsa-miR-23b-3p

0.771975008

7.498577826

3.24E-05

0.001579

5p+hsa-miR-181d5p
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hsa-miR-200a-3p

0.658183652

7.763089612

7.47E-05

0.003094

hsa-miR-4516

0.934291267

7.36976701

7.37E-05

0.003094

hsa-miR-182-5p

0.932501672

6.00293535

8.62E-05

0.003398

hsa-miR-424-5p

1.084347818

6.145867385

9.21E-05

0.003465

hsa-miR-574-5p

0.820694589

6.141846943

0.000102221

0.00368

hsa-miR-200b-3p

0.675654992

8.805182004

0.000154295

0.005323

hsa-miR-454-3p

0.872746351

5.743828142

0.000163859

0.005427

hsa-miR-503-5p

0.975523549

5.938059394

0.000171438

0.00546

hsa-miR-141-3p

0.800140832

8.907529076

0.000199229

0.00611

hsa-miR-26b-5p

0.641654495

6.731487943

0.000209159

0.006185

hsa-miR-208a-3p

0.88556572

5.168248707

0.00024902

0.006898

hsa-miR-575

0.929494714

5.954303571

0.000249922

0.006898

hsa-miR-890

0.73987247

4.745216212

0.000272278

0.007272

hsa-miR-543

0.660411144

5.842595315

0.000317425

0.008213

hsa-miR-1244

0.705662352

5.083340114

0.000440419

0.010665

hsa-miR-548j-5p

0.75946626

4.540336558

0.000450803

0.010665

hsa-miR-574-3p

0.618761442

5.965869674

0.000435249

0.010665

hsa-miR-30e-5p

0.662575328

6.067893517

0.000480997

0.011063

hsa-miR-532-5p

0.886478227

4.983202547

0.000503638

0.011271

hsa-miR-183-5p

0.637532302

7.587820411

0.000576733

0.012567

hsa-miR-1193

0.778121149

4.632546463

0.000633815

0.012759

hsa-miR-203a-5p

0.686125709

5.48522501

0.00060626

0.012759

hsa-miR-342-3p

0.683114525

6.968303599

0.000632288

0.012759
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hsa-miR-770-5p

0.688826731

4.865118807

0.000678022

0.012759

hsa-miR-186-5p

0.665128366

6.496676235

0.000701143

0.012901

hsa-miR-4524a-5p

0.781112515

4.320978851

0.000761145

0.013701

hsa-miR-584-3p

0.61519964

5.963074174

0.000858649

0.014812

hsa-miR-221-5p

0.918942184

4.913733762

0.000984765

0.016308

hsa-miR-10b-5p

0.641117456

5.658376151

0.001031569

0.016426

hsa-miR-630

0.931622917

5.501069566

0.001020109

0.016426

hsa-miR-1915-3p

0.680540353

4.52535032

0.001129563

0.017005

hsa-miR-412-3p

0.674832531

5.366226322

0.001121773

0.017005

hsa-miR-433-3p

0.74922012

4.065848871

0.001123644

0.017005

hsa-miR-1206

0.805985619

5.369483812

0.00118358

0.017193

hsa-miR-323a-3p

0.649267499

4.785490126

0.001166974

0.017193

hsa-miR-1266-5p

0.651261733

4.602058211

0.001565882

0.02149

hsa-miR-365a-

0.599262931

8.492296957

0.00153721

0.02149

hsa-miR-626

0.654549575

5.649534978

0.001635741

0.021498

hsa-miR-145-5p

0.632003785

4.242116854

0.001800947

0.0233

hsa-miR-181a-3p

0.625174269

6.626735658

0.002068456

0.0259

hsa-miR-610

0.917830368

4.247492359

0.002090643

0.0259

hsa-miR-101-3p

0.595136403

4.269042695

0.002273925

0.027076

hsa-miR-1304-5p

0.628756153

4.83882076

0.002289038

0.027076

hsa-miR-181c-5p

0.802463869

4.95101182

0.002565314

0.029501

3p+hsa-miR-365b3p
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hsa-miR-193b-3p

0.653152346

4.901701654

0.002725346

0.030912

hsa-miR-1276

0.755521672

4.412776369

0.002989711

0.032806

hsa-miR-1286

0.670731926

5.048223597

0.002973682

0.032806

hsa-miR-495-3p

0.662074005

5.578324049

0.003011138

0.032806

hsa-miR-96-5p

0.594252308

6.951722968

0.003299218

0.035477

hsa-miR-1908-3p

0.78052723

4.453725003

0.003447822

0.036137

hsa-miR-377-3p

0.767593458

4.530615321

0.003509564

0.036324

hsa-miR-152-3p

0.649367169

4.50296469

0.003771816

0.036515

hsa-miR-4532

0.629738302

5.569198371

0.004112009

0.037938

hsa-miR-568

0.591596212

4.78320632

0.004123648

0.037938

hsa-miR-1305

0.633569208

5.530270164

0.004505624

0.040551

hsa-miR-483-5p

0.586998515

4.539141633

0.005960153

0.04919

hsa-miR-656-3p

0.594447427

5.291681646

0.005822837

0.04919
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Appendix 2: List of 64 TGFβ-induced microRNAs that are predicted to have
binding sites to 3’UTR of p63 by miRWalk

TGFβ-induced miRNAs predicted
bound to 3'UTRp63 by miRwalk
1

hsa-miR-222-3p

2

hsa-miR-181a-5p

3

hsa-miR-190a-5p

4

hsa-miR-30d-5p

5

hsa-miR-21-5p

6

hsa-miR-22-3p

7

hsa-miR-29b-3p

8

hsa-miR-30a-5p

9

hsa-miR-146a-5p

10

hsa-miR-31-5p

11

hsa-miR-181b-5p

12

hsa-miR-181d-5p

13

hsa-miR-548d-5p

14

hsa-miR-203a-3p

15

hsa-miR-23b-3p

16

hsa-miR-200a-3p

17

hsa-miR-4516

18

hsa-miR-182-5p
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19

hsa-miR-424-5p

20

hsa-miR-574-5p

21

hsa-miR-454-3p

22

hsa-miR-503-5p

23

hsa-miR-141-3p

24

hsa-miR-26b-5p

25

hsa-miR-575

26

hsa-miR-890

27

hsa-miR-543

28

hsa-miR-1244

29

hsa-miR-548j-5p

30

hsa-miR-574-3p

31

hsa-miR-30e-5p

32

hsa-miR-532-5p

33

hsa-miR-183-5p

34

hsa-miR-1193

35

hsa-miR-342-3p

36

hsa-miR-770-5p

37

hsa-miR-186-5p

38

hsa-miR-584-3p

39

hsa-miR-221-5p

40

hsa-miR-10b-5p

41

hsa-miR-630
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42

hsa-miR-1915-3p

43

hsa-miR-412-3p

44

hsa-miR-433-3p

45

hsa-miR-1206

46

hsa-miR-323a-3p

47

hsa-miR-1266-5p

48

hsa-miR-365b-3p

49

hsa-miR-365a-3p

50

hsa-miR-145-5p

51

hsa-miR-610

52

hsa-miR-101-3p

53

hsa-miR-1304-5p

54

hsa-miR-181c-5p

55

hsa-miR-193b-3p

56

hsa-miR-1276

57

hsa-miR-1286

58

hsa-miR-495-3p

59

hsa-miR-377-3p

60

hsa-miR-4532

61

hsa-miR-568

62

hsa-miR-1305

63

hsa-miR-483-5p

64

hsa-miR-656-3p
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